{"id":161,"date":"2022-12-09T14:17:21","date_gmt":"2022-12-09T05:17:21","guid":{"rendered":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/?page_id=161"},"modified":"2026-01-26T11:51:54","modified_gmt":"2026-01-26T02:51:54","slug":"chemo-ronbun","status":"publish","type":"page","link":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/department\/center\/chemo\/chemo-ronbun\/","title":{"rendered":"\u8ad6\u6587\u30fb\u5b66\u4f1a\u767a\u8868"},"content":{"rendered":"\n<ul class=\"wp-block-list contents_menu\">\n<li><a href=\"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/department\/center\/chemo\/\" data-type=\"page\" data-id=\"141\">\u304a\u77e5\u3089\u305b<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/department\/center\/chemo\/chemo-goaisatsu\/\" data-type=\"page\" data-id=\"147\">\u3054\u3042\u3044\u3055\u3064<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/department\/center\/chemo\/chemo-shisetsu\/\" data-type=\"page\" data-id=\"151\">\u65bd\u8a2d\u7d39\u4ecb<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/department\/center\/chemo\/chemo-staff\/\" data-type=\"page\" data-id=\"154\">\u30b9\u30bf\u30c3\u30d5<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/department\/center\/chemo\/chemo-chiken\/\" data-type=\"page\" data-id=\"158\">\u6cbb\u7642\u5b9f\u7e3e<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/department\/center\/chemo\/chemo-ronbun\/\" data-type=\"page\" data-id=\"161\">\u8ad6\u6587\u30fb\u5b66\u4f1a\u767a\u8868<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/gan-center\/gansoudan\/#gansoudan\">\u304c\u3093\u76f8\u8ac7\u652f\u63f4\u30bb\u30f3\u30bf\u30fc<\/a><\/li>\n<\/ul>\n\n\n\n<div class=\"wp-block-pb-accordion-item c-accordion__item js-accordion-item no-js\" data-initially-open=\"false\" data-click-to-close=\"true\" data-auto-close=\"true\" data-scroll=\"false\" data-scroll-offset=\"0\"><h2 id=\"at-1610\" class=\"c-accordion__title js-accordion-controller\" role=\"button\">I. \u8ad6\u6587<\/h2><div id=\"ac-1610\" class=\"c-accordion__content\">\n<h4 class=\"wp-block-heading\">2025\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Shiraishi K\u3001Okada M\u3001Yamamoto S\u3001Matsubara Y\u3001Masuishi T\u3001Shimozaki K\u3001Yamamoto Y\u3001 Hirose S\u3001Sugiyama K\u3001Furuta M\u3001Machida N\u3001Takahashi N\u3001Yoshii T\u3001Kito Y\u3001Tsuzuki T\u3001 Boku S\u3001Tsuchihashi K\u3001Sugaya A\u3001Takayama T\u3001Komori A\u3001Mitani S\u3001Matsumoto T\u3001Nishimura T\u3001Hirata K. The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma. Sci Rep 2025; 15:8031.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2023\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u4e2d\u6751\u9686\u4e8c, \u5927\u795e\u6b63\u5b8f, \u6a0b\u53e3\u57fa\u660e, \u9234\u6728\u7f8e\u52a0, \u85e4\u679d\u88d5\u90ce. \u3000\u7d4c\u53e3\u6297\u304c\u3093\u85ac\u6295\u4e0e\u60a3\u8005\u306b\u304a\u3051\u308b\u88dc\u6b63QT \u9593\u9694\u5ef6\u9577\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u3000\u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u96d1\u8a8c2023; 59:374-380.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2022\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Kawasaki H, Hoshikawa M, Kyoden Y, Iijima T, Kojima H, Yamamoto J. A locally advanced pancreatic body cancer presenting common bile duct invasion resected via distal pancreatectomy after gemcitabine plus nab-paclitaxel chemotherapy: A case report. Int J Surg Case Rep 2022; 92:106818.<\/li>\n\n\n\n<li>Hiroshima Y, Tamaki Y, Sawada T, Murakami M, Ishida T, Saitoh T, Kojima H, Okumura T, Sakurai H. A case report of radiotherapy for skull lesions of Langerhans cell histiocytosis with dural invasion. Cancer Diagn Progn 2022 ;2:258-262.<\/li>\n\n\n\n<li>\u5cf6\u7530\u6d69\u548c. \u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u5358\u5264\u6295\u4e0e\u60a3\u8005\u306b\u304a\u3051\u308binfusion reaction\u767a\u73fe\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u30ea\u30b9\u30af\u56e0\u5b50\u306b\u95a2\u3059\u308b\u8abf\u67fb. \u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u96d1\u8a8c2022; 58:1298-1302.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2021\u5e74<\/h4>\n\n\n\n<ol style=\"list-style-type:1\" class=\"wp-block-list\">\n<li>Suzuki H, Yamada T, Sugaya A, Ueyama S, Yamamoto Y, Moriwaki T, Hyodo I. Retrospective analysis for the efficacy and safety of nivolumab in advanced gastric cancer patients according to ascites burden. Int J Clin Oncol 2021; 26:370-377. <\/li>\n\n\n\n<li>Zhang X, Yamamoto Y, Wang X, Sato M, Imanishi M, Sugaya A, Hirose M, Endo S, Moriwaki T, Yamato K, Hyodo I. MDM4 as a prognostic factor for patients with gastric cancer with low expression of p53. Anticancer Res 2021; 41:1475-1483.<\/li>\n\n\n\n<li>\u4e09\u6a4b\u5f70\u4e00, \u5ee3\u7560\u5e83\u5b9f, \u5c0f\u5cf6\u5bdb, \u67f3\u5ddd\u5fb9. \u7de9\u548c\u30b1\u30a2\u533b\u7642\u306b\u304a\u3051\u308b\u6b6f\u79d1\u533b\u5e2b\u3068\u6b6f\u79d1\u885b\u751f\u58eb\u306e\u5f79\u5272\u3063\u3066\u3001\u30ca\u30f3\u30c0\uff1f \u88dc\u7db4\u81e8\u5e8a 2021; 54:56-83.<\/li>\n\n\n\n<li>Moriwaki T, Gosho M, Sugaya A, Yamada T, Yamamoto Y, Hyodo I. Optimal maintenance strategy for first-line oxaliplatin-containing therapy with or without bevacizumab in patients with metastatic colorectal cancer: a meta-analysis. Cancer Res Treat 2021; 53:703-713.<\/li>\n\n\n\n<li>Wang X, Yamamoto Y, Imanishi M, Zhang X, Sato M, Sugaya A, Hirose M, Endo S, Natori Y, Moriwaki T, Yamato K, Hyodo I. Enhanced G1 arrest and apoptosis via MDM4\/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling. Oncol Lett 2021; 22:558.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2019\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Tanaka K, Toyota S, Akiyama M, Wakimoto N, Nakamura Y, Najima Y, Doki N, Kakihana K, Igarashi A, Kobayashi T, Ohashi K, Kudo D,Shinagawa A, Takano H, Fujio T, Okoshi Y, Hori M, Kumagai T, Saito T, Mukae J, Yamamoto K, Tsutsumi I, Komeno T, Yoshida C, Yamamoto M, and Kojima H; on behalf of the Ochanomizu Hematology Study Group. Efficacy and safety of weekly\u3000cyclophosphamide-bortezomib-dexamethasone(CBD) regimen as induction therapy prior to autologous stem cell transplantation in Japanese patients with newly diagnosed multiple myeloma. -A phase 2 multicenter trial-Acta Haematologica 141:111-118,2019.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0e\u4f75\u5b58\u75be\u60a3\u306e\u3042\u308b\u304c\u3093\u60a3\u8005\u306b\u304a\u3051\u308b\u85ac\u7269\u76f8\u4e92\u4f5c\u7528\uff5e\u6d88\u5316\u6027\u6f70\u760d\uff5e\uff0e\u85ac\u5c4070\uff087\uff09\uff0c55-60\uff0c2019<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2018\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u9ad8\u7530\u6e05\u5b50\uff0e\u5916\u6765\u3060\u3051\u3067\u306a\u304f\u5730\u57df\u3078\u51fa\u308b\uff01\u5316\u5b66\u7642\u6cd5\u3092\u53d7\u3051\u308b\u60a3\u8005\u3092\u652f\u3048\u308b\u7d99\u7d9a\u770b\u8b77\u306e\u5b9f\u8df5\uff0e\u5916\u6765\u770b\u8b772018\uff1b23\uff1a43-48\uff1a<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2017\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Fukushima M, Okoshi Y, Fukazawa K, Koshino M, Ishiguro S, Mitsuhashi S, Saitoh H, Iijima T, Kojima H, Hori M. A case of lymphoplasmacytic lymphoma presenting diarrhea and joint pain, successfully diagnosed by MYD88 mutation analysis. Intern Med 2017; 56:847-851.<\/li>\n\n\n\n<li>\u8c37\u5ddd\u9053\u6d69, \u5c71\u53e3\u606d\u5b50, \u5927\u6c5f\u548c\u7d00, \u7fbd\u77f3\u9756\u6d69, \u77f3\u91ce\u306f\u308b\u307f, \u77f3\u6e21\u52c7, \u4f0a\u85e4\u5b5d\u7f8e, \u5927\u77f3\u6bc5, \u9d28\u4e0b\u660c\u6674, \u6728\u6751\u670b\u6587, \u5c0f\u6c60\u548c\u4fca, \u7c73\u91ce\u7422\u54c9, \u4f50\u85e4\u7d14\u4e00, \u4f50\u85e4\u5b8f\u559c, \u4f50\u85e4\u85e4\u592b, \u4f50\u85e4\u7950\u4e8c, \u767d\u5ddd\u6d0b\u5b50, \u54c1\u5ddd\u7be4\u53f8, \u5fb3\u6c38\u771f\u5f13, \u702c\u53e3\u96c5\u4eba, \u6e05\u7530\u80b2\u7537, \u9ad8\u6751\u6d69\u514b, \u9577\u8c37\u5ddd\u96c4\u4e00, \u8af8\u5ca1\u4fe1\u88d5, \u5c0f\u5cf6\u5bdb, \u5927\u8d8a\u9756. \u8328\u57ce\u770c\u5408\u540c\u8f38\u8840\u7642\u6cd5\u59d4\u54e1\u4f1a\u767a\u8db3\u5f8c5\u5e74\u9593\u306e\u6d3b\u52d5. \u65e5\u672c\u8f38\u8840\u7d30\u80de\u6cbb\u7642\u5b66\u4f1a\u8a8c 2017; 63:630-633.<\/li>\n\n\n\n<li>Yoshida K, Fujisawa F, Kojima H, Takeyasu N. Hemodynamic collapse due to the stenosis of 4 pulmonary veins in a patient with mediastinal tumor. Clin Case Rep 2017; 5:1030-1031.<\/li>\n\n\n\n<li>Fukushima M, Okoshi Y, Fukazawa K, Koshino M, Ishiguro S, Mitsuhashi S, Saitoh H, Iijima T, Kojima H, Hori M. A case of lymphoplasmacytic lymphoma presenting diarrhea and joint pain, successfully diagnosed by MYD88 mutation analysis. Intern Med 2017; 56:847-851.<\/li>\n\n\n\n<li>Ohgami M, Bando H, Ishiguro H, Tsuda M, Toriguchi N, Aogi K, Toi M, Masuda N, Mitsuhashi S, Kurosawa A, Homma M. Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer. Ann Oncol 2017; 28:2888-2889.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2016\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Sugaya A, Ishiguro S, Mitsuhashi S, Abe M, Hashimoto I, Kaburagi T, Kojima H. Interstitial lung disease associated with trastuzumab monotherapy: A report of 3 cases. Mol Clin Oncol 2016; 6:229-232.<\/li>\n\n\n\n<li>\u8429\u539f\u4f50\u6075\u5b50\u3001\u6c38\u6c5f\u7f8e\u9999\u5b50\u3001\u72e9\u91ce\u4fca\u5e78\u3001\u5c0f\u5cf6\u5bdb. \u76ae\u819a\u8ee2\u79fb\u3092\u304d\u305f\u3057\u305f\u591a\u767a\u6027\u9aa8\u9ac4\u816b. \u76ae\u819a\u81e8\u5e8a 2016; 58:1515-1518.<\/li>\n\n\n\n<li>Kanaya M, Shibuya K, Hirochika R, Kanemoto M, Ohashi K, Okada M, Wagatsuma, Cho Y, Kojima H, Teshima T, Imamura M, Sakamaki H, Shibuya A. Soluble DNAM-1, as a predictive biomarker for acute graft-versus-host disease. PLoS One 2016; 11(6):e0154173.<\/li>\n\n\n\n<li>Iguchi-Manaka A, Okumura G, Kojima H, Cho Y, Hirochika R, Bando H, Sato T, Yoshikawa H, Hara H, Shibuya A, Shibuya K. Increased soluble CD155 in the serum of cancer patients. PLoS One 2016; 11(4):e0152982.<\/li>\n\n\n\n<li>Yamamoto M, Ohashi K, Kakihana K, Nakamura Y, Komeno T, Kojima H, Morita S, Sakamaki H. A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following autologous peripheral blood stem cell transplantation. Mol Clin Oncology 2016; 4:965-970.<\/li>\n\n\n\n<li>Ohgami M, Kaburagi T, Kurosawa A, Homma M. Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer. Lung Cancer. 2016; 101:9-10.<\/li>\n\n\n\n<li>Ohgami M, Homma M, Suzuki Y, Naito K, Yamada M, Mitsuhashi S, Fujisawa F, Kojima H, Kaburagi T, Uchiumi K, Yamada Y, Bando H, Hara H, Takei K. A Simple High-Performance Liquid Chromatography for Determining Lapatinib and Erlotinib in Human Plasma. Ther Drug Monit. 2016; 38(6): 657-662.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2015\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Inada K, Okoshi Y, Cho Y, Saito H, Iijima T, Hori M, Kojima H. Availability of circulating microRNAs as a biomarker for early diagnosis of diffuse large B-cell lymphoma. Open J Blood Diseases 2015; 5:48-58.<\/li>\n\n\n\n<li>Kudo D, Ohashi K, Komeno T, Nakamura Y, Shinagawa A, Yoshida C, Katsura Y, Ota I, Kakihana K, Kobayashi T, Kawai N, Kato A, Arai A, Yamamoto K, Toyota S, Kumagai T, Ohwada A, Miki T, Hori M, Okoshi Y, Kojima H, Sakamaki H. Efficacy and safety of bortezomib-containing induction chemotherapy for autologous stem cell transplantation-eligible Japanese multiple myeloma patients -A phase 2 multicenter trial-. Int J Myeloma 2015; 5:15-22.<\/li>\n\n\n\n<li>Cho Y, Hori M, Okoshi Y, Fujisawa F, Shinagawa A, Kudo D, Komeno T, Yoshida C, Katsura Y, Ota I, Shimizu S, Kamoshita M, Sasaki K, Tanaka K, Mukai YH, Kojima H. Measurement of proteasome activity in peripheral blood mononuclear cells as an indicator of susceptibility to bortezomib-induced severe neurological adverse events in patients with multiple myeloma. Acta Haematologica 2015; 134:25-31.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2013\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Morishita A, Mitsuhashi S, Fujisawa F, Hirano M, Kojima H. Usefulness of bevacizumab with paclitaxel for advanced breast cancer -a case report. Gan To Kagaku Ryoho (in Japanese) 2013; 40:761-764.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2012\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Ohta S, Cho Y, Shibata M, Nagai K, Iijima T, Saito H, Asakura H, Kojima H.\u3000Possibility of molecular targeting therapy for the treatment of cancer of unknown primary origin by analysis of intracellular signaling molecules. Exp Ther Med 2012; 3:547-9.<\/li>\n\n\n\n<li>Ohta S, Cho Y, Oshima S, Hosoya O, Juni K, Kojima H. Oxaliplatin-induced acute-onset thrombocytopenia and hemorrhage: Case report and review of the literature. Oncol Lett 2012; 3:1297-300.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2010\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u9ed2\u6728\u6df3\u5b50. \u30a2\u30ed\u30de\u30bb\u30e9\u30d4\u30fc\u306e\u6d3b\u7528\u3068\u52b9\u7528. \u5916\u6765\u770b\u8b77. 2010; 4\u30fb5\u6708\u53f7, 67-76.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2009\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009; 10(2):115-24.<\/li>\n<\/ol>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-pb-accordion-item c-accordion__item js-accordion-item no-js\" data-initially-open=\"false\" data-click-to-close=\"true\" data-auto-close=\"true\" data-scroll=\"false\" data-scroll-offset=\"0\"><h2 id=\"at-1611\" class=\"c-accordion__title js-accordion-controller\" role=\"button\">II. \u5b66\u4f1a\u767a\u8868<\/h2><div id=\"ac-1611\" class=\"c-accordion__content\">\n<h4 class=\"wp-block-heading\">2025\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Sunakawa Y\u3001Inoue E\u3001Kotani D\u3001Denda T\u3001Inagaki C\u3001Kashiwada T\u3001Horita Y\u3001Sugaya A\u3001 Suwa Y\u3001Ohta T\u3001Kuramochi H\u3001Oshima K\u3001Shiozawa M\u3001Yuki S\u3001Tsuji A\u3001Muro K\u3001Ichikawa W\u3001Fujii M.\u3000Encorafenib and cetuximab with\/without binimetinib therapies for BRAF-mutated metastatic colorectal cancer patients with prognostic factors: the BEETS trial (JACCRO CC-18). ASCO-GI\u3001 2025.1\uff08USA\u3001 \u30b5\u30f3\u30d5\u30e9\u30f3\u30b7\u30b9\u30b3\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u77f3\u9ed2\u613c\u543e\u3001\u8352\u6728\u771e\u88d5\u3001\u77f3\u6a4b\u8087\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u5927\u95a2\u745e\u6cbb\u3001\u4e94\u982d\u4e09\u79c0\u3001\u702c\u5c71\u4f91\u4eae\u3001\u6749\u5c71\u6cbb\u4e45\u3001\u5c0f\u5cf6\u5bdb. \u30be\u30eb\u30d9\u30c4\u30ad\u30b7\u30de\u30d6\u6295\u4e0e\u306b\u304a\u3051\u308b\u30c1\u30fc\u30e0\u533b\u7642\u306e\u5b9f\u8df5 \u7b2c97\u56de\u65e5\u672c\u80c3\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012025.3\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3\u3001\u9ad8\u7530\u6e05\u5b50\u3001\u4e09\u6a4b\u5f70\u4e00\u3001\u5ddd\u5d0e\u666e\u53f8\u3001\u85e4\u5c3e\u9ad8\u884c\u3001\u5927\u795e\u6b63\u5b8f\u3001\u7acb\u539f\u8302\u6a39\u3001\u7530\u4e2d\u548c\u7f8e\u3001\u4e0a\u7530\u771f\u7531\u7f8e\u3001\u5c0f\u5cf6\u5bdb.\u3000\u5316\u5b66\u7642\u6cd5\u30b3\u30f3\u30b5\u30eb\u30c6\u30fc\u30b7\u30e7\u30f3\u30c1\u30fc\u30e0\u3068\u816b\u760d\u5185\u79d1\u306e\u5f79\u5272 \u7b2c22\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u7dcf\u4f1a\u30012025.3\uff08\u795e\u6238\uff09<\/li>\n\n\n\n<li>\u5c0f\u5cf6\u5065\u4e00\u3001\u5927\u795e\u6b63\u5b8f\u3001\u7acb\u539f\u8302\u6a39\u3001\u5cf6\u7530\u6d69\u548c\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u67f4\u3053\u306e\u307f\u3001\u690d\u7530\u6e05\u5b5d\u3001\u9234\u6728\u667a\u8cb4\u3001\u5ca1\u90e8\u96c4\u592a\u3001\u9234\u6728\u7f8e\u52a0\uff0e\u30a2\u30f3\u30c8\u30e9\u30b5\u30a4\u30af\u30ea\u30f3\u7cfb\u6297\u304c\u3093\u85ac\u306b\u3088\u308b\u304c\u3093\u6cbb\u7642\u95a2\u9023\u5fc3\u6a5f\u80fd\u969c\u5bb3\u306b\u304a\u3051\u308b\u5fc3\u96fb\u56f3\u306e\u6709\u7528\u6027\u8a55\u4fa1\uff0e\u7b2c14\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\u30012025.3\uff08\u6a2a\u6d5c\uff09<\/li>\n\n\n\n<li>\u00a0\u67f3\u5ddd\u5fb9\u3001\u897f\u6751\u6587\u543e\u3001\u5965\u6751\u654f\u4e4b\u3001\u7530\u6751\u745b\u91cc\u3001\u539f\u91ce\u6676\u4ec1\u3001\u677e\u6c38\u62d3\u4e5f\u3001\u5ee3\u5d8b\u60a0\u4e00\u3001\u7ae0\u7af6\u7acb\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u77f3\u9ed2\u613c\u543e\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u5ddd\u5d0e\u666e\u53f8\u3001\u9577\u4e95\u5b8f\u6a39\u3001\u548c\u7530\u9686\u5fd7\u3001\u6301\u7530\u96c4\u5b50\u3001\u6b66\u5185\u4fdd\u654f\u3001\u5c71\u7e23\u61b2\u53f8\u3001\u83c5\u91ce\u76f4\u7f8e\u3001\u5185\u7530\u6587\u5f66\u3001\u798f\u6fa4\u667a\u3001\u6b66\u5ddd\u5bdb\u6a39 .\u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u306b\u304a\u3051\u308b\u982d\u9838\u90e8\u60aa\u6027\u816b\u760d\u6cbb\u7642\u306e\u5404\u79d1\u306e\u9023\u643a\u306b\u3064\u3044\u3066 \u7b2c 33 \u56de\u8328\u57ce\u770c\u6b6f\u79d1\u533b\u5b66\u4f1a\u30012025.3 \uff08\u6c34\u6238\uff09<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2024\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u83c5\u8c37\u660e\u5fb3\u3001\u77f3\u9ed2\u613c\u543e\u3001\u5c0f\u5cf6\u5bdb.\u3000\u3000MSH2\u75c5\u7684\u30d0\u30ea\u30a2\u30f3\u30c8\u3092\u8a8d\u3081\u305f\u8179\u76f4\u7b4b\u539f\u767a\u306e\u591a\u5f62\u578b\u6a2a\u7d0b\u7b4b\u8089\u816b\u306e\u4e00\u4f8b\u3000\u7b2c21\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u7dcf\u4f1a \u30012024.2\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3\u3001\u77f3\u9ed2\u613c\u543e\u3001\u5c0f\u5cf6\u5bdb\u3001\u77f3\u6a4b\u8087\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u702c\u5c71\u4f91\u4eae\u3001\u5927\u95a2\u745e\u6cbb\u3001\u5c71\u53e3\u53f3\u771f\u3001\u8352\u6728\u771e\u88d5\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u4e94\u982d\u4e09\u79c0\u3001\u5929\u8c9d\u8ce2\u4e8c.\u3000HER2\u967d\u6027\u5207\u9664\u4e0d\u80fd\u30fb\u9032\u884c\u80c3\u764c\u306b\u5bfe\u3059\u308b\u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u30c7\u30eb\u30af\u30b9\u30c6\u30ab\u30f3\u306e\u6d88\u5316\u5668\u6bd2\u6027\u306e\u5f8c\u65b9\u8996\u76845\u4f8b\u306e\u691c\u8a0e\u3000\u7b2c96\u56de\u65e5\u672c\u80c3\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012024.2\uff08\u4eac\u90fd\uff09<\/li>\n\n\n\n<li>\u67f3\u5ddd\u5fb9\u3001\u9577\u4e95\u5b8f\u6a39\u3001\u897f\u6fa4\u5320\u3001\u897f\u6751\u6587\u543e\u3001\u77f3\u9ed2\u613c\u543e\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u5c0f\u5cf6\u5bdb\u3001\u6301\u7530\u96c4\u5b50\u3001\u677e\u91d1\u5948\u7dd2\u3001\u6c34\u91ce\u5b5d\u5b50\u3001\u6b66\u5185\u4fdd\u654f\u3001\u5c71\u7e23\u61b2\u53f8\u3001\u83c5\u91ce\u76f4\u7f8e\u3001\u5185\u7530\u6587\u5f66\u3001\u798f\u6ca2\u667a\u3001\u6b66\u5ddd\u5bdb\u6a39\u5f53\u9662\u3067\u53e3\u8154\u304c\u3093\u306b\u5bfe\u3057\u3066\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u85acPembrolizumab\u3092\u4f7f\u7528\u3057\u305f7\u4f8b \u7b2c32\u56de\u8328\u57ce\u770c\u6b6f\u79d1\u533b\u5b66\u4f1a\u30012024.3\uff08\u8328\u57ce\uff09<\/li>\n\n\n\n<li>\u77e2\u82b1 \u4fe1\u4e9c\u3001\u83c5\u8c37 \u660e\u5fb3\u3001\u85e4\u5c3e \u9ad8\u884c\u3001\u4e09\u6a4b \u5f70\u4e00\u3001\u77f3\u9ed2 \u613c\u543e\u3001\u6589\u85e4 \u4ec1\u662d\u3001\u5c0f\u5cf6 \u5bdb.\u539f\u767a\u4e0d\u660e\u304c\u3093\u3068\u3057\u3066\u7d39\u4ecb\u3055\u308c\u7279\u767a\u6027\u591a\u4e2d\u5fc3\u6027Castleman\u75c5(iMCD)\u3068\u8a3a\u65ad\u3057\u305f\u591a\u767a\u30ea\u30f3\u30d1\u7bc0\u816b\u8139\u306e\u4e00\u4f8b\u65e5\u672c\u5185\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u3000\u3053\u3068\u306f\u3058\u3081\u30012024.4\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3\u3001\u65e5\u5409\u96c5\u4e5f.\u3000A case of anorectal malignant melanoma treated with immune checkpoint inhibitor after anorectal sparing surgery and irradiation \u7b2c110\u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u7dcf\u4f1a\u30012024.5\u3000\uff08\u5fb3\u5cf6)<\/li>\n\n\n\n<li>\u702c\u5c71\u4f91\u4eae\u3001\u6749\u5c71\u6cbb\u4e45\u3001\u5c71\u53e3\u53f3\u771f\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u5927\u95a2\u745e\u6cbb\u3001\u8352\u6728\u771e\u88d5\u3001\u4e94\u982d\u4e09\u79c0\u3001\u5929\u8c9d\u8ce2\u4e8c.\u3000\u6d88\u5316\u7ba1\u7570\u7269\u306b\u304a\u3051\u308b\u5185\u8996\u93e1\u7684\u7570\u7269\u9664\u53bb\u8853\u306e\u6709\u52b9\u6027\u306e\u691c\u8a0e JDDW2024\u30012024.10\uff08\u795e\u6238\uff09<\/li>\n\n\n\n<li>\u5c71\u5ca1\u6b63\u6cbb\u3001\u4e94\u982d\u4e09\u79c0\u3001 \u702c\u5c71\u4f91\u4eae\u3001 \u6749\u5c71\u6cbb\u4e45\u3001\u5c71\u53e3\u53f3\u771f\u3001 \u672c\u591a\u5bdb\u4e4b\u3001 \u77f3\u6a4b\u8087\u3001 \u83c5\u8c37\u660e\u5fb3\u3001 \u5927\u95a2\u745e\u6cbb\u3001\u8352\u6728\u771e\u88d5\u3001\u5929\u8c9d\u8ce2\u4e8c.\u300010mm\u4ee5\u4e0b\u306e\u65e9\u671f\u5927\u8178\u764c\u3068\u9ad8\u7570\u578b\u5ea6\u817a\u816b\u306e\u5185\u8996\u93e1\u7684\u6cbb\u7642\u72b6\u6cc1\u3000JDDW2024\u30012024.10\uff08\u795e\u6238\uff09<\/li>\n\n\n\n<li>\u5800 \u5149\u96c4\u3001\u85e4\u5c3e\u9ad8\u884c\u3001\u9ed2\u5ddd\u5b89\u6e80\u3001\u9577\u8c37\u5ddd\u96c4\u4e00\u3001\u5c0f\u5cf6\u5bdb\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u4e09\u6a4b\u5f70\u4e00\u3001\u77f3\u9ed2\u613c\u543e. \u5358\u4e00\u65bd\u8a2d\u306b\u304a\u3051\u308b\u30a8\u30ed\u30c4\u30ba\u30de\u30d6\u306e\u9577\u671f\u6cbb\u7642\u304c\u53ef\u80fd\u3060\u3063\u305f\u75c7\u4f8b\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e. \u7b2c86\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012024.10\uff08\u4eac\u90fd\uff09<\/li>\n\n\n\n<li>\u9ad8\u7530\u6e05\u5b50\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u4e09\u6a4b\u5f70\u4e00\u3001\u5ddd\u5d0e\u666e\u53f8\u3001\u85e4\u5c3e\u9ad8\u884c\u3001\u5c0f\u5cf6\u5bdb\u3001\u5927\u795e\u6b63\u5b8f\u3001\u7acb\u539f\u8302\u6a39\u3001\u7530\u4e2d\u548c\u7f8e\u3001\u4e0a\u7530\u771f\u7531\u7f8e.\u3000\u5316\u5b66\u7642\u6cd5\u30b3\u30f3\u30b5\u30eb\u30c6\u30fc\u30b7\u30e7\u30f3\u30c1\u30fc\u30e0\u306e\u6d3b\u52d5\u5831\u544a\u3000\u7b2c62\u56de\u5168\u56fd\u81ea\u6cbb\u4f53\u75c5\u9662\u5b66\u4f1a\u30012024.11\uff08\u65b0\u6f5f\uff09<\/li>\n\n\n\n<li>\u67cf\u5f69\u7e54\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u5ee3\u5d8b\u60a0\u4e00\u3001\u5927\u795e\u6b63\u5b8f\u3001\u52a9\u5ddd\u5343\u7d75\u3001\u7cf8\u8cc0\u667a\u5b50\u3001\u91ce\u5d0e\u8ca2.\u3000\u81b5\u81d3\u304c\u3093\u30fb\u80c6\u9053\u304c\u3093\u6559\u5ba4\u306e\u53d6\u308a\u7d44\u307f\u306e\u52b9\u679c\u3000\u7b2c62\u56de\u5168\u56fd\u81ea\u6cbb\u4f53\u75c5\u9662\u5b66\u4f1a\u30012024.11\uff08\u65b0\u6f5f\uff09<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2023\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u767d\u77f3\u548c\u5bdb\u3001\u6749\u5c71\u572d\u53f8\u3001 \u6fa4\u4e95\u5eb7\u5f25\u3001 \u4e0b\u5d5c\u5553\u592a\u90ce\u3001 \u5ca1\u7530\u771f\u592e\u3001\u677e\u539f\u7950\u6a39\u3001 \u53e4\u7530\u5149\u5bdb\u3001\u5ee3\u702c\u512a\u3001\u5c0f\u68ee\u6893\u3001\u4e09\u8c37\u8aa0\u4e00\u90ce\u3001\u6734\u5c06\u6e90\u3001\u897f\u6751\u5c1a\u3001 \u571f\u6a4b\u8ce2\u53f8\u3001 \u6728\u85e4\u967d\u4ecb\u3001 \u83c5\u8c37\u660e\u5fb3\u3001 \u821b\u77f3\u4fca\u6a39\u3001 \u677e\u672c\u4fca\u5f66\u3001 \u7b51\u6728\u9686\u96c4\u3001 \u5409\u4e95 \u8cb4\u5b50\u3001 \u5e73\u7530\u8ce2\u90ce. \u9032\u884c\u518d\u767a\u98df\u9053\u6241\u5e73\u4e0a\u76ae\u764c\u306e\u4e00\u6b21\u6cbb\u7642\u306b\u304a\u3051\u308bFOLFOX\u7642\u6cd5\u306b\u95a2\u3059\u308b\u591a\u65bd\u8a2d\u5f8c\u65b9\u8996\u7684\u7814\u7a76. \u7b2c\uff12\uff10\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2023.3\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n<li>\u9234\u6728\u5609\u6cbb\u3001\u7530\u6751\u667a\u5b8f\u3001 \u8352\u6728\u771e\u88d5\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u5c0f\u5cf6\u5bdb\u3001\u5e02\u585a\u4e9c\u7531\u7f8e\u3001\u5cf6\u7530\u6d69\u548c\u3001\u5c71\u4e0b\u3086\u3046\u304b\u3001\u9234\u6728\u7f8e\u52a0. \u30df\u30b3\u30d5\u30a7\u30ce\u30fc\u30eb\u9178\u306e\u8840\u6db2\u4e2d\u6fc3\u5ea6\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u306b\u3088\u308a\u30b9\u30c6\u30ed\u30a4\u30c9\u62b5\u6297\u6027\u514d\u75ab\u95a2\u9023\u809d\u969c\u5bb3\u306e\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3092\u8a66\u307f\u305f\u80ba\u817a\u764c\u306e\u4e00\u75c7\u4f8b. \u7b2c\uff12\uff10\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2023.3\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3\u3001\u77f3\u9ed2\u613c\u543e\u3001\u5c0f\u5cf6\u5bdb. \u5f53\u9662\u306b\u304a\u3051\u308b\u553e\u6db2\u817a\u764c\u75c7\u4f8b\u306b\u304a\u3051\u308b\u30e9\u30ed\u30c8\u30ec\u30af\u30c1\u30cb\u30d6\u306e\u4f7f\u7528\u7d4c\u9a13. \u7b2c\uff12\uff10\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2023.3\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n<li>Shinichi Nishina, Naoki Izawa, Megumu Watabe, Toshihiko Matsumoto, Masato Kataoka, Akinori Sugaya, Tomomi Kashiwada, Eiji Oki, Akitaka Makiyama, Yoshihisa Yaguchi, Takashi Ohta, Tatsuya Toyokawa, Yasuyuki Miura, Kazuma Kobayashi, Yosuke Kito, Osamu Muto, Yoshinori Kagawa, Hironaga Satake, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa. RAS status in circulating-tumor DNA after chemotherapy in RAS mutant mCRC: the RASMEX study (JACCRO CC-17)\u3000ESMO-GI2023\u3000\u30b9\u30da\u30a4\u30f3,\u30d0\u30eb\u30bb\u30ed\u30ca\uff082023.6\uff09<\/li>\n\n\n\n<li>\u77f3\u5802\u4f73\u4e16\u3001\u5c71\u53e3\u53f3\u771f\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u77f3\u6a4b\u8087\u3001\u658e\u85e4\u8aa0.\u3000\u5f53\u9662\u306e\u304c\u3093\u30b2\u30ce\u30e0\u5916\u6765\u306b\u304a\u3051\u308b\u8a8d\u5b9a\u907a\u4f1d\u30ab\u30a6\u30f3\u30bb\u30e9\u30fc\u306e\u95a2\u308f\u308a\u3000\u907a\u4f1d\u30ab\u30a6\u30f3\u30bb\u30ea\u30f3\u30b0\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012023.7\uff08\u9577\u91ce\uff09<\/li>\n\n\n\n<li>\u690d\u7530\u6e05\u5b5d. \u6d3b\u6027\u578b\u30d3\u30bf\u30df\u30f3 D3 \u88fd\u5264\u306e\u9069\u6b63\u4f7f\u7528\u306b\u95a2\u3059\u308b\u85ac\u5264\u5e2b\u306e\u53d6\u308a\u7d44\u307f\u3000\u7b2c61\u56de&nbsp;\u5168\u56fd\u81ea\u6cbb\u4f53\u75c5\u9662\u5b66\u4f1a 2023.9\uff08\u5317\u6d77\u9053\uff09<\/li>\n\n\n\n<li>\u6749\u5c71\u6cbb\u4e45\u3001\u5927\u95a2\u745e\u6cbb\u3001\u5c71\u53e3\u53f3\u771f\u3001\u702c\u5c71\u4f91\u4eae\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u4e94\u982d\u4e09\u79c0\u3001\u8352\u6728\u771e\u88d5\u3001\u5929\u8c9d\u8ce2\u4e8c.\u3000S\u72b6\u7d50\u8178\u8ef8\u637b\u8ee2\u3092\u304d\u305f\u3057\u305f44\u4f8b\u306e\u691c\u8a0e\u3000JDDW2023 2023.11\uff08\u795e\u6238\uff09<\/li>\n\n\n\n<li>\u5c71\u5ca1\u6b63\u6cbb\u3001\u4e94\u982d\u4e09\u79c0\u3001\u77f3\u6a4b\u8087\u3001\u6749\u5c71\u6cbb\u4e45\u3001\u5c71\u53e3\u53f3\u771f\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u5927\u95a2\u745e\u6cbb\u3001\u8352\u6728\u771e\u88d5\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u65e5\u5409\u96c5\u4e5f.\u3000\u5927\u8178\u30a4\u30ec\u30a6\u30b9\u3092\u304d\u305f\u3057\u305f87\u4f8b\u306e\u691c\u8a0e\u3000JDDW2023 2023.11\uff08\u795e\u6238\uff09<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2022\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u83c5\u8c37\u660e\u5fb3. \u5e0c\u5c11\u907a\u4f1d\u5b50\u5909\u7570\u3092\u8003\u616e\u3057\u305f\u982d\u9838\u90e8\u764c\u306e\u6cbb\u7642\u6226\u7565. \u5f53\u9662\u3067\u306e\u553e\u6db2\u817a\u764c\u75c7\u4f8b\u306b\u304a\u3051\u308b\u30e9\u30ed\u30c8\u30ec\u30af\u30c1\u30cb\u30d6\u306e\u4f7f\u7528\u7d4c\u9a13. \u7b2c31\u56de\u65e5\u672c\u982d\u981a\u90e8\u5916\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u306a\u3089\u3073\u306b\u5b66\u8853\u96c6\u4f1a\u30fb\u30d0\u30a4\u30a8\u30eb\u85ac\u54c1\u682a\u5f0f\u4f1a\u793e\u5171\u50ac\u30bb\u30df\u30ca\u30fc\u30002022.3\uff08\u5927\u962a\uff09<\/li>\n\n\n\n<li>Ohgami M, Itoga T, Kojima H. Retrospective analysis of the association of geriatric assessment and outcomes in elderly gastric cancer patients. \u7b2c19\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a 2022.2\uff08\u4eac\u90fd\uff09<\/li>\n\n\n\n<li>\u5cf6\u7530\u6d69\u548c\uff0e\u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u5358\u5264\u6295\u4e0e\u60a3\u8005\u306b\u304a\u3051\u308binfusion reaction\u4e88\u9632\u306b\u5bfe\u3059\u308b\u524d\u6295\u85ac\u306e\u6709\u7528\u6027. \u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a2022 2022.3\uff08\u5bae\u57ce\uff09<\/li>\n\n\n\n<li>\u5c0f\u5cf6\u5bdb. Comprehensive Oral Care\u306b\u3088\u308b\u60a3\u8005Well-being\u3078\u306e\u8ca2\u732e\u3000\uff5e\u533b\u79d1\u6b6f\u79d1\u9023\u643a\u306e\u5728\u308a\u65b9\u3092\u8003\u3048\u308b\uff5e\u3000\u7b2c\uff13\uff17\u56de\u65e5\u672c\u75c5\u9662\u6b6f\u79d1\u53e3\u8154\u5916\u79d1\u5354\u8b70\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u96c6\u4f1a\uff08\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff09, 2022.11\uff08\u5e55\u5f35\uff09<\/li>\n\n\n\n<li>\u77f3\u5802\u4f73\u4e16\u3001\u5927\u795e\u6b63\u5b8f\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u9f4b\u85e4\u8aa0\u3001\u963f\u90e8\u9999\u7e54\u3001\u77f3\u9ed2\u613c\u543e. \u304c\u3093\u30b2\u30ce\u30e0\u30d7\u30ed\u30d5\u30a1\u30a4\u30ea\u30f3\u30b0\u691c\u67fb\u306b\u304a\u3051\u308b\u751f\u6b96\u7d30\u80de\u7cfb\u5217\u306e\u75c5\u7684variant\u306b\u5bfe\u3059\u308b\u591a\u8077\u7a2e\u30bf\u30b9\u30af\u30fb\u30b7\u30a7\u30a2\u30ea\u30f3\u30b0\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e. \u7b2c\uff12\uff18\u56de\u65e5\u672c\u907a\u4f1d\u6027\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012022.6\uff08web\uff09<\/li>\n\n\n\n<li>\u5824\u80b2\u4ee3\u3001\u5c71\u672c\u6b63\u82f1\u3001 \u85e4\u5c3e\u9ad8\u884c\u3001 \u54c1\u5ddd\u7be4\u53f8\u3001 \u5c0f\u6749\u4fe1\u6625\u3001 \u9ad8\u91ce\u5f25\u5948\u3001\u5c71\u672c\u6643\u3001 \u718a\u8c37\u9686\u5fd7\u3001 \u4e09\u6728\u5fb9\u3001 \u5de5\u85e4\u5927\u8f14\u3001 \u8c4a\u7530\u8302\u96c4\u3001\u4e2d\u6751\u88d5\u4e00\u3001 \u5ddd\u4e95\u4fe1\u5b5d\u3001 \u5927\u6a4b\u4e00\u8f1d\u3001 \u7c73\u91ce\u7422\u54c9\u3001\u5c0f\u5cf6\u5bdb. \u9aa8\u9ac4\u816b\u306b\u5bfe\u3059\u308bVRD\u7642\u6cd5\u3068\u4f4e\u7528\u91cf\u30b7\u30af\u30ed\u30d5\u30a9\u30b9\u30d5\u30a1\u30df\u30c9+\u30dc\u30eb\u30c6\u30be\u30df\u30d6\u306b\u3088\u308b\u5e79\u7d30\u80de\u52d5\u54e1\u30fb\u81ea\u5bb6\u79fb\u690d\u306e\u6709\u52b9\u6027. \u7b2c\uff14\uff14\u56de\u65e5\u672c\u9020\u8840\u30fb\u514d\u75ab\u7d30\u80de\u7642\u6cd5\u5b66\u4f1a\u7dcf\u4f1a, 2022.5\uff08\u6a2a\u6d5c\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f. \u30da\u30b0\u30d5\u30a3\u30eb\u30b0\u30e9\u30b9\u30c1\u30e0\u306e\u6295\u4e0e\u30bf\u30a4\u30df\u30f3\u30b0\u304c\u767a\u71b1\u6027\u597d\u4e2d\u7403\u6e1b\u5c11\u75c7\u306b\u4e0e\u3048\u308b\u5f71\u97ff\uff08\u7b2c5\u5831\uff09.\u3000\u7b2c\uff13\uff12\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a, 2022.9\uff08\u9ad8\u5d0e\uff09<\/li>\n\n\n\n<li>\u7530\u5c71\u85ab\uff0e\u5916\u6765\u304c\u3093\u5316\u5b66\u7642\u6cd5\u306b\u304a\u3051\u308b\u85ac\u5264\u5e2b\u306e\u53d6\u308a\u7d44\u307f. \u8328\u57ce\u304c\u3093\u30d5\u30a9\u30fc\u30e9\u30e0, 2022.10\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li>\u7acb\u539f\u8302\u6a39. \u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u306b\u304a\u3051\u308b\u6297\u304c\u3093\u85ac\u6c5a\u67d3\u306e\u7d99\u7d9a\u7684\u306a\u74b0\u5883\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0.\u3000\u7b2c\uff16\uff10\u56de\u5168\u56fd\u81ea\u6cbb\u4f53\u75c5\u9662\u5b66\u4f1a, 2022.11\uff08\u6c96\u7e04\uff09<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2021\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Ohgami M, Yamashita M, Tsuboyama S, Itoga T, Kojima H. Retrospective analysis of the association of geriatric assessment and treatment outcomes in elderly patients with gastrointestinal cancer. \u7b2c18\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2021.2\uff08Web\u958b\u50ac\uff09<\/li>\n\n\n\n<li>\u7acb\u539f\u8302\u6a39\u3001\u5927\u795e\u6b63\u5b8f\u3001\u5e02\u585a\u4e9c\u7531\u7f8e\u3001\u77f3\u5ddd\u6d0b\u8f14\u3001\u5cf6\u7530\u6d69\u548c\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u67f4\u3053\u306e\u307f\u3001\u5c71\u4e0b\u771f\u4ee5\u3001\u576a\u5c71\u52dd\u5e73\u3001\u5343\u8449\u5e03\u5b63\u5b50\u3001\u9234\u6728\u9ebb\u7d17\u5b50\u3001\u9234\u6728\u7f8e\u52a0. \u4e73\u764c\u60a3\u8005\u3078\u306e\u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u521d\u56de\u6295\u4e0e\u6642\u306b\u304a\u3051\u308bInfusion reaction \u767a\u73fe\u306b\u95a2\u308f\u308b\u30ea\u30b9\u30af\u56e0\u5b50\u306e\u691c\u8a0e. NEXT IP 2021 \uff5eNEXT Generation for Ibaraki Pharmacist\uff5e\uff0c2021.3\uff08Web\u958b\u50ac\uff09<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2020\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Sugaya A\uff0c Ueyama S\uff0c Suzuki H\uff0c Yamada T\uff0c Yamamoto Y\uff0c Moriwaki T\uff0c Hyodo I\uff0e Retrospective analysis for efficacy and safety of nivolumab in advanced gastric cancer patients (pts) with malignant ascites\uff0e Gastrointestinal Cancers Symposium 2020 (ASCO-GI 2020) Abst\uff0e392 (JCO\uff0e2020\uff0e38\uff0e4_suppl\uff0e392) 2020\uff0e1 (San Francisco\uff0cUSA)<\/li>\n\n\n\n<li>\u5cf6\u7530\u6d69\u548c\u3001\u5927\u795e\u6b63\u5b8f\u3001\u7acb\u539f\u8302\u6a39\u3001\u5e02\u585a\u4e9c\u7531\u7f8e\u3001\u77f3\u5ddd\u6d0b\u8f14\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u67f4\u3053\u306e\u307f\u3001\u9234\u6728\u7f8e\u52a0\uff0e\u5f53\u9662\u306b\u304a\u3051\u308b\u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u521d\u56de\u6295\u4e0e\u6642\u306eInfusion reaction\u767a\u73fe\u7387\u3068\u524d\u6295\u85ac\u306e\u95a2\u4fc2\u306b\u3064\u3044\u3066\uff0e\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a2020\uff0c2020\uff0e3\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n<li>\u67f4\u3053\u306e\u307f\u3001\u5927\u795e\u6b63\u5b8f\u3001\u7acb\u539f\u8302\u6a39\u3001\u5e02\u585a\u4e9c\u7531\u7f8e\u3001\u77f3\u5ddd\u6d0b\u8f14\u3001\u5cf6\u7530\u6d69\u548c\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u9234\u6728\u7f8e\u52a0\uff0e\u304c\u3093\u85ac\u7269\u7642\u6cd5\u306b\u304a\u3051\u308b\u8077\u696d\u6027\u66b4\u9732\u5bfe\u7b56\u8abf\u67fb\uff0e\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a2020\uff0c2020\uff0e3\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3. \u5f53\u9662\u306b\u304a\u3051\u308b\u5207\u9664\u4e0d\u80fd\u9032\u884c\u30fb\u518d\u767a\u5927\u8178\u764c\u306eTAS-102\u306e\u4f7f\u7528\u7d4c\u9a13. \u7b2c106\u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u7dcf\u4f1a, 2020.8 (\u8a8c\u4e0a\u767a\u8868)<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3. \u5f53\u9662\u306b\u304a\u3051\u308b\u5207\u9664\u4e0d\u80fd\u9032\u884c\u30fb\u518d\u767a\u80c3\u764c\u306b\u5bfe\u3059\u308b\u30cb\u30dc\u30eb\u30de\u30d6\u306e\u4f7f\u7528\u6210\u7e3e. \u7b2c92\u56de\u65e5\u672c\u80c3\u764c\u5b66\u4f1a\u7dcf\u4f1a, 2020.8\uff08\u8a8c\u4e0a\u767a\u8868\uff09<\/li>\n\n\n\n<li>\u7acb\u539f\u8302\u6a39\u3001\u5927\u795e\u6b63\u5b8f\u3001\u5e02\u585a\u4e9c\u7531\u7f8e\u3001\u77f3\u5ddd\u6d0b\u8f14\u3001\u5cf6\u7530\u6d69\u548c\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u67f4\u3053\u306e\u307f\u3001\u5c71\u4e0b\u771f\u4ee5\u3001\u576a\u5c71\u52dd\u5e73\u3001\u5343\u8449\u5e03\u5b63\u5b50\u3001\u9234\u6728\u9ebb\u7d17\u5b50\u3001\u9234\u6728\u7f8e\u52a0. \u9589\u9396\u5f0f\u85ac\u7269\u79fb\u9001\u30b7\u30b9\u30c6\u30e0\u5c0e\u5165\u524d\u5f8c\u306b\u304a\u3051\u308b\u6297\u304c\u3093\u85ac\u66dd\u9732\u72b6\u6cc1\u8abf\u67fb. \u7b2c30\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a, 2020.10\uff08Web\u958b\u50ac\uff09<\/li>\n\n\n\n<li>\u7acb\u539f\u8302\u6a39\u3001\u5927\u795e\u6b63\u5b8f\u3001\u5e02\u585a\u4e9c\u7531\u7f8e\u3001\u77f3\u5ddd\u6d0b\u8f14\u3001\u5cf6\u7530\u6d69\u548c\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u67f4\u3053\u306e\u307f\u3001\u5c71\u4e0b\u771f\u4ee5\u3001\u576a\u5c71\u52dd\u5e73\u3001\u5343\u8449\u5e03\u5b63\u5b50\u3001\u9234\u6728\u9ebb\u7d17\u5b50\u3001\u9234\u6728\u7f8e\u52a0. \u533b\u7642\u5f93\u4e8b\u8005\u306e\u6297\u304c\u3093\u85ac\u66dd\u9732\u5bfe\u7b56\u306e\u5b9f\u614b\u8abf\u67fb\uff5e\u8328\u57ce\u770c\u5185\u306e\u8077\u696d\u6027\u66dd\u9732\u5bfe\u7b56\u306e\u5747\u3066\u3093\u5316\u3092\u76ee\u6307\u3057\u3066\uff5e\u3000\u8328\u57ce\u304c\u3093\u30d5\u30a9\u30fc\u30e9\u30e02020, 2020.11\uff08Web\u958b\u50ac\uff09<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2019\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u77f3\u9ed2\u613c\u543e\u3001\u5c0f\u5cf6\u5bdb\u3001\u5800\u5149\u96c4\u3001\u7530\u6751\u667a\u5b8f\u3001\u85e4\u679d\u771f\u53f8\u3001\u77f3\u5802\u4f73\u4e16\u3001\u658e\u85e4\u8aa0\u3001BRACAnalysis\u691c\u67fb\u3068PARP\u963b\u5bb3\u5264\u300c\u30aa\u30e9\u30d1\u30ea\u30d6\u300d\u306e\u51e6\u65b9\u3092\u53ef\u80fd\u3068\u3059\u308b\u969b\u306b\u5fc5\u8981\u306a\u9662\u5185\u591a\u8077\u7a2e\u306b\u3088\u308b\u30c1\u30fc\u30e0\u533b\u7642\u3068\u305d\u306e\u5fdc\u7528\uff0e\u7b2c17\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\uff0c2019.7(\u4eac\u90fd)<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u9999\u53d6\u53f2\u83dc\u3001\u6839\u672c\u660c\u5f66\u3001\u5e73\u4e95\u5229\u5e78\u3001\u732a\u702c\u6210\u53f2\u3001\u6e21\u908a\u96c5\u660e\u3001\u6cc9\u73b2\u5b50\u3001\u79cb\u672c\u5149\u4fe1\u3001\u6e21\u9089\u5553\u592a\u3001\u5c0f\u5c71\u7530\u8061\u3001\u672c\u9593\u771f\u4eba\u3001\u9ed2\u6fa4\u8c4a\u5f66\uff0e\u85ac\u5264\u5e2b\u306b\u3088\u308b\u591a\u65bd\u8a2d\u5171\u540c\u81e8\u5e8a\u7814\u4fee\u306e\u4f53\u5236\u69cb\u7bc9. \u7b2c28\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a\uff0c2019.1\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li>\u576a\u5c71\u52dd\u5e73\u3001\u5927\u795e\u6b63\u5b8f\u3001\u5c71\u4e0b\u771f\u4ee5\u3001\u5e02\u585a\u4e9c\u7531\u7f8e\u3001\u5de5\u85e4\u6709\u672a\u3001\u4e94\u8012\u4f73\u592e\u91cc\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u5f8c\u85e4\u3072\u304b\u308b\u3001\u9ed2\u6fa4\u8c4a\u5f66\uff0e\u5916\u6765\u304c\u3093\u5316\u5b66\u7642\u6cd5\u306b\u304a\u3051\u308b\u670d\u85ac\u6307\u5c0e\u306b\u3064\u3044\u3066\uff0e\u7b2c28\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a\uff0c2019.1\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li>\u5cf6\u7530\u6d69\u548c\u3001\u5927\u795e\u6b63\u5b8f\u3001\u7acb\u539f\u8302\u6a39\u3001\u6df1\u6fa4\u4e9c\u5b63\u5b50\u3001\u9234\u6728\u4e00\u885b\u3001\u5ca9\u4e0a\u667a\u7f8e\u3001\u77f3\u5ddd\u6d0b\u8f14\u3001\u4e94\u8012\u4f73\u592e\u91cc\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u8352\u6728\u771e\u88d5\u3001\u5c0f\u5cf6\u5bdb\u3001\u9ed2\u6fa4\u8c4a\u5f66\uff0e\u514d\u75ab\u6291\u5236\u30fb\u5316\u5b66\u7642\u6cd5\u60a3\u8005\u306b\u304a\u3051\u308b\uff22\u578b\u809d\u708e\u30a6\u30a4\u30eb\u30b9\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u5b9f\u65bd\u72b6\u6cc1\u8abf\u67fb\uff0e\u7b2c28\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a\uff0c2019.1\uff08\u6c34\u6238\uff09\uff08\u512a\u79c0\u6f14\u984c\uff09<\/li>\n\n\n\n<li>\u7acb\u539f\u8302\u6a39\u3001\u5927\u795e\u6b63\u5b8f\u3001\u6df1\u6fa4\u4e9c\u5b63\u5b50\u3001\u9234\u6728\u4e00\u885b\u3001\u5ca9\u4e0a\u667a\u7f8e\u3001\u77f3\u5ddd\u6d0b\u8f14\u3001\u5cf6\u7530\u6d69\u548c\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u9ed2\u6fa4\u8c4a\u5f66\uff0e\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\u88fd\u5264\u306e\u8907\u6570\u56de\u4f7f\u7528\u3068\u7d4c\u6e08\u6027\u306b\u95a2\u3059\u308b\u691c\u8a0e\uff0e\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a2019\uff0c2019.3\uff08\u672d\u5e4c\uff09<\/li>\n\n\n\n<li>\u5c0f\u5cf6\u53cb\u6075\u3001\u5927\u795e\u6b63\u5b8f\u3001\u7acb\u539f\u8302\u6a39\u3001\u6df1\u6fa4\u4e9c\u5b63\u5b50\u3001\u9234\u6728\u4e00\u885b\u3001\u5ca9\u4e0a\u667a\u7f8e\u3001\u77f3\u5ddd\u6d0b\u8f14\u3001\u5cf6\u7530\u6d69\u548c\u3001\u9ed2\u6fa4\u8c4a\u5f66\uff0e\u30da\u30b0\u30d5\u30a3\u30eb\u30b0\u30e9\u30b9\u30c1\u30e0\u306e\u6295\u4e0e\u30bf\u30a4\u30df\u30f3\u30b0\u304c\u767a\u71b1\u6027\u597d\u4e2d\u7403\u6e1b\u5c11\u75c7\u306e\u767a\u751f\u7387\u306b\u4e0e\u3048\u308b\u5f71\u97ff\uff0e\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\uff0c2019.3\uff08\u672d\u5e4c\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\u3001\u5c71\u4e0b\u771f\u4ee5\u3001\u5e02\u585a\u4e9c\u7531\u7f8e\u3001\u576a\u5c71\u52dd\u5e73\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u5f8c\u85e4\u3072\u304b\u308b\u3001\u5c0f\u5cf6\u5bdb\u3001\u9ed2\u6fa4\u8c4a\u5f66\uff0e \u5916\u6765\u5316\u5b66\u7642\u6cd5\u306b\u304a\u3051\u308b\u91cd\u7be4\u306a\u6709\u5bb3\u4e8b\u8c61\u306e\u767a\u751f\u72b6\u6cc1\u306b\u95a2\u3059\u308b\u691c\u8a0e\uff0e\u7b2c17\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2019.7\uff08\u4eac\u90fd\uff09<\/li>\n\n\n\n<li>\u4e94\u8012\u4f73\u592e\u91cc\u3001\u5927\u795e\u6b63\u5b8f\u3001\u5e02\u585a\u4e9c\u7531\u7f8e\u3001\u576a\u5c71\u52dd\u5e73\u3001\u5cf6\u7530\u6d69\u548c\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u9234\u6728\u9ebb\u7d17\u5b50\u3001\u8352\u6728\u771e\u88d5\u3001\u5c0f\u5cf6\u5bdb\u3001\u9234\u6728\u7f8e\u52a0\uff0e\u514d\u75ab\u6291\u5236\u30fb\u5316\u5b66\u7642\u6cd5\u60a3\u8005\u306b\u304a\u3051\u308bB\u578b\u809d\u708e\u30a6\u30a4\u30eb\u30b9\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u5b9f\u65bd\u72b6\u6cc1\u8abf\u67fb\uff0e\u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u95a2\u6771\u30d6\u30ed\u30c3\u30af\u7b2c49\u56de\u5b66\u8853\u5927\u4f1a\uff0c2019.8\uff08\u5c71\u68a8\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\u3001\u5c0f\u5cf6\u5bdb\u3001\u5c71\u4e0b\u771f\u4ee5\u3001\u5e02\u585a\u4e9c\u7531\u7f8e\u3001\u4e94\u8012\u4f73\u592e\u91cc\u3001\u576a\u5c71\u52dd\u5e73\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u9234\u6728\u7f8e\u52a0\uff0e\u5916\u6765\u5316\u5b66\u7642\u6cd5\u306b\u304a\u3051\u308b\u9ad8\u9f62\u8005\u306e\u6a5f\u80fd\u8a55\u4fa1\u3068\u6cbb\u7642\u306e\u5b9f\u614b\u8abf\u67fb\uff0e\u7b2c29\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a\uff0c2019.11\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n<li>\u67f4\u3053\u306e\u307f\u3001\u5927\u795e\u6b63\u5b8f\u3001\u7acb\u539f\u8302\u6a39\u3001\u5e02\u585a\u4e9c\u7531\u7f8e\u3001\u77f3\u5ddd\u6d0b\u8f14\u3001\u5cf6\u7530\u6d69\u548c\u3001\u5c0f\u5cf6\u53cb\u6075\u3001\u9234\u6728\u7f8e\u52a0\uff0e\u304c\u3093\u85ac\u7269\u7642\u6cd5\u306b\u304a\u3051\u308b\u8077\u696d\u6027\u66b4\u9732\u5bfe\u7b56\u8abf\u67fb\uff0e\u7b2c29\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a\uff0c2019.12\uff08\u8328\u57ce\uff09<\/li>\n\n\n\n<li>\u6d77\u85e4\u4f73\u4ee3\u5b50\u3001\u5c0f\u67f4\u5e78\u5b50\uff0e\u5916\u6765\u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u521d\u56de\u53d7\u8a3a\u60a3\u8005\u306e\u6c17\u6301\u3061\u306e\u3064\u3089\u3055\u306e\u5b9f\u614b\uff0e\u7b2c28\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a\uff0c2019.1\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li>\u7cf8\u8cc0\u667a\u5b50\u3001\u7530\u4e2d\u548c\u7f8e\u3001A\u75c5\u9662\u5916\u6765\u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u306b\u304a\u3051\u308b\u514d\u75ab\u95a2\u9023\u526f\u4f5c\u7528\u51fa\u73fe\u6642\u306e\u53d7\u8a3a\u6307\u5c0e\u306e\u691c\u8a0e\uff0e\u7b2c29\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a\uff0c2019\uff0c12(\u571f\u6d66)<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2018\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Kudo D, Komeno T, Yoshida C, Ota TI, Ohashi K, Kakihana K , Kobayashi T, Doki N, Najima Y, Igarashi A, Hori M, Okoshi Y, Fujio T, Shinagawa A, Yamamoto M, Takano H, Kumagai T, Yamamoto K, Toyota S, Nakamura Y, Kojima H.Efficacy and safety of once-weekly cyclophosphamide-bortezomib-dexamethasone(CBD) regimen as induction therapy prior to autologous stem cell transplantation in Japanese patients with newly diagnosed multiple myeloma.-a phase 2 multicenter trial- 60th annual meeting of the American Society of Hematology, 2018.12(San Diego, U.S.A)<\/li>\n\n\n\n<li>\u77f3\u9ed2\u613c\u543e\u3001\u5c0f\u5cf6\u5bdb\u3001\u98ef\u5cf6\u4e00\u98db\u3001\u4e09\u6a4b\u5f70\u4e00\u3001\u85e4\u679d\u771f\u53f8\u3001\u7530\u6751\u667a\u5b8f\u3001\u5927\u8d8a\u9756\u3001\u5800\u5149\u96c4\uff0e\u60a3\u8005\u6559\u80b2\u3092\u542b\u3081\u305f\u30c1\u30fc\u30e0\u533b\u7642\u306b\u3088\u308b\u30c8\u30e9\u30d9\u30af\u30c6\u30b8\u30f3\u306e\u5b89\u5168\u306a\u6295\u4e0e\u7ba1\u7406\u65b9\u6cd5\uff0e\u7b2c16\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012018.7\uff08\u795e\u6238\uff09<\/li>\n\n\n\n<li>Ohgami M, Bando H, Ishiguro H, Tsuda M, Toriguchi N, Masuda N, Toi M, Mitsuhashi S, Kurosawa A, Homma M. Therapeutic drug monitoring of lapatinib for assessing lapatinib-induced skin rash in patients with breast cancer. The 16th International Congress of Therapeutic Drug Monitoring &amp; Clinical Toxicology, 2018.9(Brisbane, Australia)\uff08\u65e5\u672cTDM\u5b66\u4f1a\u300cIATDMCT\u5b66\u8853\u5927\u4f1a\u300d\u6d3e\u9063\u8cde\uff08\u6d77\u8001\u539f\u8cde\uff09\u53d7\u8cde\uff09<\/li>\n\n\n\n<li>\u5c0f\u5cf6\u53cb\u6075\u3001\u5927\u795e\u6b63\u5b8f\u3001\u6df1\u6fa4\u4e9c\u5b63\u5b50\u3001 \u7acb\u539f\u8302\u6a39\u3001\u99d2\u7530\u90a6\u5f66\u3001 \u7acb\u539f\u8302\u6a39\u3001\u5c71\u4e0b\u771f\u4ee5\u3001\u9234\u6728\u4e00\u885b\u3001\u5ca9\u4e0a\u667a\u7f8e\u3001\u77f3\u5ddd\u6d0b\u8f14\u3001\u5f8c\u85e4\u3072\u304b\u308b\u3001\u9ed2\u6fa4\u8c4a\u5f66. \u6297\u304c\u3093\u85ac\u8abf\u88fd\u30fb\u6295\u4e0e\u306b\u4f7f\u7528\u3059\u308b\u9589\u9396\u5f0f\u63a5\u7d9a\u5668\u5177\u306e\u6bd4\u8f03\u691c\u8a0e. \u7b2c27\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a\u30012018<\/li>\n\n\n\n<li>\u83ca\u5730\u5343\u6625\u3001\u9ad8\u7530\u6e05\u5b50\u3001 \u5824\u307e\u3086\u307f. \u5916\u6765\u5316\u5b66\u7642\u6cd5\u306b\u3088\u308b\u6709\u5bb3\u4e8b\u8c61\u3092\u7406\u7531\u306b\u6551\u6025\u5916\u6765\u3092\u53d7\u8a3a\u3057\u305f\u60a3\u8005\u306e\u5b9f\u614b. \u7b2c27\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a\u30012018 .<\/li>\n\n\n\n<li>\u5c0f\u6797\u4f50\u77e5\u5b50\u3001\u5927\u69fb\u5948\u7f8e\u3001\u5824\u307e\u3086\u307f. A\u75c5\u9662\u5916\u6765\u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u306b\u304a\u3051\u308b\u6709\u75c7\u6642\u306e\u96fb\u8a71\u76f8\u8ac7\u306e\u73fe\u72b6. \u7b2c27\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a\u30012018 .<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2017\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Hori M, Ikebe E, Fajardo L, Ikebe T, Kojima H, Iha H. Evidence of SLAM7 expression among multiple lineages of hematologic malignancy. \u7b2c79\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2017.<\/li>\n\n\n\n<li>\u7a32\u7530\u52dd\u91cd, \u5927\u8d8a\u9756, \u5f35\u6109\u7d00\u5b50, \u98ef\u5d8b\u9054\u751f, \u5800\u5149\u96c4, \u5c0f\u5cf6\u5bdb. \u30ea\u30f3\u30d1\u7bc0\u7d44\u7e54\u3092\u7528\u3044\u308bmicroRNA\u89e3\u6790\u306b\u9069\u3057\u305f\u5185\u5728\u6027\u907a\u4f1d\u5b50\u306e\u9078\u51fa. \u7b2c76\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2017.<\/li>\n\n\n\n<li>\u5927\u8d8a\u9756, \u77f3\u6e21\u52c7, \u5c0f\u6c60\u548c\u5f66, \u7c73\u91ce\u7422\u54c9, \u4f50\u85e4\u7950\u4e8c, \u9577\u8c37\u5ddd\u96c4\u4e00, \u4f50\u85e4\u85e4\u592b, \u9d28\u4e0b\u660c\u6674, \u4f0a\u85e4\u5b5d\u7f8e, \u54c1\u5ddd\u7be4\u53f8, \u5fb3\u6c38\u771f\u5f13, \u4f50\u85e4\u5b8f\u559c, \u767d\u5ddd\u6d0b\u5b50, \u702c\u53e3\u96c5\u4eba, \u6728\u6751\u670b\u6587, \u6e05\u7530\u80b2\u7537, \u4f50\u85e4\u7d14\u4e00, \u7a32\u8449\u980c\u4e00, \u5c0f\u5cf6\u5bdb, \u8af8\u5ca1\u4fe1\u88d5. \u7523\u79d1\u65bd\u8a2d\u3067\u9069\u5207\u306b\u7ba1\u7406\u3055\u308c\u305f\u8840\u6db2\u88fd\u5264\u306e\u8fd4\u5374\u30fb\u8ee2\u7528\u306e\u5b9f\u73fe\u6027\u306b\u3064\u3044\u3066\u306e\u8abf\u67fb\u7814\u7a76\u2015\u8328\u57ce\u770c\u5408\u540c\u8f38\u8840\u59d4\u54e1\u4f1a. \u7b2c65\u56de\u65e5\u672c\u8f38\u8840\u30fb\u7d30\u80de\u6cbb\u7642\u5b66\u4f1a\u7dcf\u4f1a, 2017.<\/li>\n\n\n\n<li>\u4e0a\u59bb\u884c\u5247, \u5c0f\u5cf6\u5bdb, \u6cbc\u77e5\u5948\u4fdd\u5b50, \u4e8c\u5bae\u6cbb\u5f66. \u5de8\u6838\u7403\u9020\u8840\u306b\u304a\u3051\u308b\u6297\u8840\u5c0f\u677f\u6297\u4f53\u306e\u5f71\u97ff. \u2015\u514d\u75ab\u6027\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\u30e2\u30c7\u30eb\u30de\u30a6\u30b9\u3092\u7528\u3044\u305f\u691c\u8a0e\u2015\u3000\u7b2c39\u56de\u65e5\u672c\u8840\u6813\u6b62\u8840\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2017.<\/li>\n\n\n\n<li>\u77f3\u9ed2\u613c\u543e, \u5c0f\u5cf6\u5bdb, \u98ef\u5cf6\u4e00\u98db, \u85e4\u679d\u771f\u53f8, \u7530\u6751\u667a\u5b8f, \u85e4\u5c3e\u9ad8\u884c, \u5800\u5149\u96c4. \u814b\u7aa9\u30ea\u30f3\u30d1\u7bc0\u306e\u307f\u306b\u8ee2\u79fb\u3092\u6709\u3059\u308b\u5973\u6027\u306e\u539f\u767a\u4e0d\u660e\u764c (\u6f5c\u5728\u6027\u4e73\u764c) \u306f\u4e73\u68d2\u5168\u6458\u51fa\u8853\u3092\u7701\u7565\u3067\u304d\u308b\u304b. \u7b2c15\u56de\u65e5\u672c\u81e8\u5e8a\u5b66\u8853\u96c6\u4f1a, 2017.<\/li>\n\n\n\n<li>\u5c0f\u5cf6\u5065\u4e00, \u5927\u795e\u6b63\u5b8f, \u6df1\u6fa4\u4e9c\u5b63\u5b50, \u7acb\u539f\u8302\u6a39, \u99d2\u7530\u90a6\u5f66, \u5c71\u4e0b\u771f\u4ee5, \u9234\u6728\u4e00\u885b, \u5ca9\u4e0a\u667a\u7f8e, \u77f3\u5ddd\u6d0b\u8f14, \u9ed2\u6fa4\u8c4a\u5f66. \u6297\u304c\u3093\u5264\u8abf\u88fd\u306b\u4f7f\u7528\u3059\u308b\u9589\u9396\u5f0f\u63a5\u7d9a\u5668\u5177\u306e\u6bd4\u8f03\u691c\u8a0e. \u7b2c26\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a, 2017.<\/li>\n\n\n\n<li>\u5c71\u4e0b\u771f\u4ee5, \u5927\u795e\u6b63\u5b8f, \u99d2\u7530\u90a6\u5f66, \u6df1\u6fa4\u4e9c\u5b63\u5b50, \u5c0f\u5cf6\u5065\u4e00, \u7acb\u539f\u8302\u6a39, \u9234\u6728\u4e00\u885b, \u5ca9\u4e0a\u667a\u7f8e, \u77f3\u5ddd\u6d0b\u8f14, \u9ed2\u6fa4\u8c4a\u5f66. \u7d4c\u53e3\u6297\u304c\u3093\u85ac\u9069\u6b63\u4f7f\u7528\u306e\u305f\u3081\u306e\u81e8\u5e8a\u691c\u67fb\u5024\u6d3b\u7528\u306b\u4fc2\u308b\u8abf\u67fb. \u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2017.<\/li>\n\n\n\n<li>\u5ca9\u4e0a\u667a\u7f8e, \u5927\u795e\u6b63\u5b8f, \u7acb\u539f\u8302\u6a39, \u9ed2\u6fa4\u8c4a\u5f66. \u30a4\u30ea\u30ce\u30c6\u30ab\u30f3\u6295\u4e0e\u4e2d\u306e\u8153\u8179\u7b4b\u75d9\u6523\u306b\u828d\u85ac\u7518\u8349\u6e6f\u304c\u6709\u52b9\u3067\u3042\u3063\u305f\u4e00\u4f8b. \u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2017.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u9ad8\u529b\u898f\u96c4, \u9234\u6728\u7f8e\u52a0, \u8352\u6728\u771e\u88d5, \u9ed2\u6fa4\u8c4a\u5f66. \u5f53\u9662\u306b\u304a\u3051\u308bB\u578b\u809d\u708e\u518d\u6d3b\u6027\u5316\u5bfe\u7b56\u306e\u53d6\u308a\u7d44\u307f. \u7b2c15\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2017.<\/li>\n\n\n\n<li>Ohgami M, Kaburagi T, Shiozawa T, Hizawa N, Kurosawa A, Homma M. Effect of proton pump inhibitors co-administration on the plasma concentration of erlotinib in patients with non-small cell lung cancer (2nd report). The 15th Congress of IATDMCT, 2017.<\/li>\n\n\n\n<li>\u4e94\u8012\u4f73\u592e\u91cc, \u9ad8\u529b\u898f\u96c4, \u9df2\u6d25\u5bff\u5f25, \u718a\u7530\u9ebb\u8863, \u78ef\u7530\u9054\u4e5f, \u5bae\u5ddd\u5c1a\u7f8e, \u6a4b\u672c\u5e7e\u592a, \u9ed2\u6fa4\u8c4a\u5f66. \u5f53\u9662\u306b\u304a\u3051\u308b\u9759\u6ce8\u6297\u83cc\u85ac\u4f7f\u7528\u91cf\u53ca\u3073\u5404\u7a2e\u83cc\u306e\u85ac\u5264\u8010\u6027\u7387\u306e\u73fe\u72b6\u306b\u3064\u3044\u3066. \u7b2c56\u56de\u5168\u56fd\u81ea\u6cbb\u4f53\u75c5\u9662\u5b66\u4f1a, 2017.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u5c0f\u5cf6\u5bdb, \u9ed2\u6fa4\u8c4a\u5f66. \u5916\u6765\u304c\u3093\u5316\u5b66\u7642\u6cd5\u306b\u304a\u3051\u308b\u6551\u6025\u53d7\u8a3a\u306e\u5b9f\u614b\u8abf\u67fb. \u7b2c27\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a, 2017.<\/li>\n\n\n\n<li>\u5f8c\u85e4\u3072\u304b\u308b, \u5927\u795e\u6b63\u5b8f, \u99d2\u7530\u90a6\u5f66, \u7acb\u539f\u8302\u6a39, \u6df1\u6fa4\u4e9c\u5b63\u5b50, \u5c71\u4e0b\u771f\u4ee5, \u9234\u6728\u4e00\u885b, \u5ca9\u4e0a\u667a\u7f8e, \u77f3\u5ddd\u6d0b\u8f14, \u5c0f\u5cf6\u53cb\u6075, \u9ed2\u6fa4\u8c4a\u5f66. \u30ec\u30ca\u30ea\u30c9\u30df\u30c9\u306e\u51e6\u65b9\u5b9f\u614b\u8abf\u67fb. \u7b2c28\u56de\u8328\u57ce\u770c\u85ac\u5264\u5e2b\u5b66\u8853\u5927\u4f1a, 2017.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u4e09\u6a4b\u5f70\u4e00, \u9ed2\u6fa4\u8c4a\u5f66, \u672c\u9593\u771f\u4eba. \u30d5\u30a7\u30cb\u30c8\u30a4\u30f3\u4f75\u7528\u6642\u306b\u30e9\u30d1\u30c1\u30cb\u30d6\u306e\u8840\u4e2d\u6fc3\u5ea6\u304c\u4f4e\u4e0b\u3057\u305f\u4e00\u75c7\u4f8b. \u7b2c38\u56de\u65e5\u672c\u81e8\u5e8a\u85ac\u7406\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2017.<\/li>\n\n\n\n<li>\u6728\u6751\u76f4\u7f8e, \u9ad8\u7530\u6e05\u5b50. \u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u306b\u304a\u3051\u308b\u6297\u304c\u3093\u5264\u306b\u3088\u308b\u9759\u8108\u708e\u3068\u8840\u7ba1\u5916\u6f0f\u51fa\u306e\u767a\u751f\u72b6\u6cc1. \u7b2c26\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a, 2017.<\/li>\n\n\n\n<li>\u5927\u5cf6\u7f8e\u5948\u5b50, \u4e2d\u7530\u516c\u7f8e, \u83ca\u5730\u5343\u6625. \u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u306b\u304a\u3051\u308b\u8925\u7621\u767a\u751f\u8981\u56e0\u306e\u691c\u8a0e. \u7b2c26\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a, 2017.<\/li>\n\n\n\n<li>\u9ad8\u7530\u6e05\u5b50, \u89d2\u7530\u76f4\u679d. \u5916\u6765\u6240\u5c5e\u304c\u3093\u5316\u5b66\u7642\u6cd5\u770b\u8b77\u8a8d\u5b9a\u770b\u8b77\u5e2b\u306e\u5728\u5b85\u7642\u990a\u652f\u63f4\u306b\u304a\u3051\u308b\u5f79\u5272. \u7b2c48\u56de\u65e5\u672c\u5728\u5b85\u770b\u8b77\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2017<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2016\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Cho Y, Inada K, Okoshi Y, Hori M, Kojima H. Comprehensive analysis of serum cytokines\/chemokines in myeloma patients for pursuing the abnormality in microenvironment and predicting the prognosis. 58th annual meeting of the American Society of Hematology, 2016.<\/li>\n\n\n\n<li>Hori M, Okoshi Y, Fujio T, Kojima H, Iha H, Ikebe E. Modulated mRNA expression profiles of a MM cell after a long-term exposure to lenalidomide. \u7b2c78\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2016.<\/li>\n\n\n\n<li>Kudo D, Komeno T, Ohashi K, Nakamura Y, Shinagawa A, Suyama T, Yoshida C, Kobayashi T, Wakimoto N, Hori M, Okoshi Y, Kumagai T, Kato A, Toyota S, Yamamoto K, Yamamoto M, Kawai N, Ohwada A, Miki T, Sakamaki H, Kojima H. Efficacy and safety of CBD induction for ASCT-eligible NDMM -A phase 2 multicenter trial- \u7b2c78\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2016.<\/li>\n\n\n\n<li>\u77f3\u9ed2\u613c\u543e, \u85e4\u6fa4\u6587\u7d75, \u5800\u5149\u96c4, \u5c0f\u5cf6\u5bdb. \u9aa8\u9ac4\u6240\u898b\u306e\u5909\u5316\u3067paclitaxel\u306b\u3088\u308b\u6cbb\u7642\u7d99\u7d9a\u3092\u6c7a\u5b9a\u3057\u8457\u52b9\u3057\u305f\u4e73\u764c\u8853\u5f8c\u518d\u767a\u9aa8\u9ac4\u764c\u816b\u75c7\u306e\u4e00\u4f8b. \u7b2c14\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2016.<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3, \u77f3\u9ed2\u613c\u543e, \u4e09\u6a4b\u5f70\u4e00, \u5c0f\u5cf6\u5bdb. \u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u95a2\u9023\u9593\u8cea\u6027\u80ba\u708e\u306e3\u4f8b. \u7b2c14\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2016.<\/li>\n\n\n\n<li>\u5f35\u6109\u7d00\u5b50, \u7a32\u7530\u52dd\u91cd, \u8d8a\u91ce\u7e6d\u5b50, \u5927\u8d8a\u9756, \u5800\u5149\u96c4, \u5c0f\u5cf6\u5bdb. \u591a\u767a\u6027\u9aa8\u9ac4\u816b\u60a3\u8005\u306e\u8840\u6e05\u4e2d\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u30fb\u30b1\u30e2\u30ab\u30a4\u30f3\u306e\u7db2\u7f85\u7684\u6e2c\u5b9a\u306b\u57fa\u3065\u304f\u75c5\u614b\u30fb\u4e88\u5f8c\u89e3\u6790. \u7b2c41\u56de\u65e5\u672c\u9aa8\u9ac4\u816b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2016.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u5742\u6771\u88d5\u5b50, \u77f3\u9ed2\u6d0b, \u9ce5\u53e3\u5c1a\u5b50, \u6d25\u7530\u840c, \u6238\u4e95\u96c5\u548c, \u5897\u7530\u614e\u4e09, \u6b66\u4e95\u656c\u53f8, \u672c\u9593\u771f\u4eba. \u30e9\u30d1\u30c1\u30cb\u30d6\u306e\u8840\u4e2d\u6fc3\u5ea6\u306b\u53ca\u307c\u3059\u670d\u7528\u30bf\u30a4\u30df\u30f3\u30b0\u3068\u30bf\u30e2\u30ad\u30b7\u30d5\u30a7\u30f3\u4f75\u7528\u306e\u5f71\u97ff. \u7b2c33\u56de\u65e5\u672cTDM\u5b66\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a, 2016.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u5185\u85e4\u52a0\u5948\u5b50, \u4e95\u5742\u90a6\u5f66, \u5c71\u4e0b\u771f\u4ee5, \u5c71\u7530\u5e79\u5b50, \u5c0f\u6cc9\u548c\u7f8e, \u9234\u6728\u4e00\u885b, \u5c0f\u5cf6\u5bdb, \u9ed2\u6fa4\u8c4a\u5f66. \u30a4\u30ea\u30ce\u30c6\u30ab\u30f3\u6295\u4e0e\u60a3\u8005\u306b\u304a\u3051\u308bMAT \u3092\u7528\u3044\u305f\u60aa\u5fc3\u30fb\u5614\u5410\u8abf\u67fb. \u7b2c26\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a, 2016.<\/li>\n\n\n\n<li>\u9234\u6728\u4e00\u885b, \u5927\u795e\u6b63\u5b8f, \u5c71\u5185\u6566, \u8fbb\u672c\u4e00\u5e73, \u5cf6\u5c45\u5fb9, \u5927\u8c37\u5e79\u4f38, \u9ed2\u6fa4\u8c4a\u5f66. \u524d\u7acb\u817a\u764c\u60a3\u8005\u306b\u304a\u3051\u308bG-CSF\u306e\u4f7f\u7528\u72b6\u6cc1\u8abf\u67fb. \u7b2c26\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a, 2016.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u9ed2\u6fa4\u8c4a\u5f66. \u5f53\u9662\u306b\u304a\u3051\u308b\u85ac\u5264\u79d1\u5916\u6765\u306e\u53d6\u308a\u7d44\u307f. \u7b2c55\u56de\u5168\u56fd\u81ea\u6cbb\u4f53\u75c5\u9662\u5b66\u4f1a, 2016.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u5742\u6771\u88d5\u5b50, \u77f3\u9ed2\u6d0b, \u9ce5\u53e3\u5c1a\u5b50, \u6d25\u7530\u840c, \u6238\u4e95\u96c5\u548c, \u5897\u7530\u614e\u4e09, \u4e09\u6a4b\u5f70\u4e00, \u9ed2\u6fa4\u8c4a\u5f66, \u672c\u9593\u771f\u4eba. \u30e9\u30d1\u30c1\u30cb\u30d6\u306e\u8840\u4e2d\u6fc3\u5ea6\u306b\u53ca\u307c\u3059\u670d\u7528\u30bf\u30a4\u30df\u30f3\u30b0\u3068\u30bf\u30e2\u30ad\u30b7\u30d5\u30a7\u30f3\u4f75\u7528\u306e\u5f71\u97ff\uff08\u7b2c2\u5831\uff09. \u7b2c37\u56de\u65e5\u672c\u81e8\u5e8a\u85ac\u7406\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2016.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u9df2\u6d25\u5bff\u5f25, \u85e4\u679d\u771f\u53f8, \u9ed2\u6fa4\u8c4a\u5f66. \u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u306b\u304a\u3051\u308b\u85ac\u5264\u5e2b\u306e\u53d6\u308a\u7d44\u307f. \u7b2c6\u56de\u81b5\u304c\u3093\u6559\u5ba4\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7, 2016.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u93d1\u6728\u5b5d\u4e4b, \u6b66\u4e95\u656c\u53f8, \u672c\u9593\u771f\u4eba. \u30d5\u30a7\u30cb\u30c8\u30a4\u30f3\u4f75\u7528\u6642\u306b\u30a8\u30eb\u30ed\u30c1\u30cb\u30d6\u306e\u8840\u4e2d\u6fc3\u5ea6\u304c\u4f4e\u4e0b\u3057\u305f\u4e00\u75c7\u4f8b. \u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2016.<\/li>\n\n\n\n<li>\u5ca9\u4e0a\u667a\u7f8e, \u5927\u795e\u6b63\u5b8f, \u8c37\u4e2d\u6566\u7f8e, \u4e95\u5742\u90a6\u5f66, \u5c71\u4e0b\u771f\u4ee5, \u6c38\u7530\u88d5\u592a\u90ce, \u9234\u6728\u4e00\u885b, \u77f3\u5ddd\u6d0b\u8f14, \u6b66\u4e95\u656c\u53f8. \u80c6\u9053\u764c\u60a3\u8005\u306b\u304a\u3051\u308b\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u6295\u4e0e\u304c\u814e\u6a5f\u80fd\u306b\u53ca\u307c\u3059\u5f71\u97ff. \u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2016.<\/li>\n\n\n\n<li>\u5927\u69fb\u5948\u7f8e, \u5c0f\u6797\u4f50\u77e5\u5b50, \u5c0f\u67f4\u5e78\u5b50. \u5916\u6765\u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u306e\u6cbb\u7642\u74b0\u5883\u306e\u73fe\u72b6\u3068\u8ab2\u984c -\u770b\u8b77\u5e2b\u306e\u60a3\u8005\u4f53\u9a13\u524d\u5f8c\u306e\u8a8d\u8b58\u306e\u5909\u5316-. \u7b2c25\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a, 2016.<\/li>\n\n\n\n<li>\u5ddd\u91ce\u8fba\u6075\u5b9f, \u83ca\u5730\u5343\u6625. \u5916\u6765\u5316\u5b66\u7642\u6cd5\u60a3\u8005\u3078\u306e\u30d7\u30e9\u30a4\u30de\u30ea\u30fc\u770b\u8b77\u3092\u901a\u3057\u3066 -\u7d99\u7d9a\u770b\u8b77\u306e\u5fc5\u8981\u6027-. \u7b2c25\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a, 2016.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2015\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Hori M, Iha H, Ikebe E, Okoshi Y, Nicole F, Koshino M, Kojima H. Cereblon\/IKZF1-3 could be prognostic markers for LND treatment to the lymphocytic malignancy. \u7b2c77\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2015.<\/li>\n\n\n\n<li>Inada K, Okoshi Y, Cho Y, Koshino M, Saito H, Iijima T, Hori M, Kojima H. Overexpression of serum miR-21 at the diagnosis is a risk factor for DLBCL recurrence. \u7b2c77\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2015.<\/li>\n\n\n\n<li>\u8d8a\u91ce\u7e6d\u5b50, \u5927\u8d8a\u9756, \u85e4\u6fa4\u6587\u7d75, \u77f3\u9ed2\u613c\u543e, \u4e09\u6a4b\u5f70\u4e00, \u5c0f\u5cf6\u5bdb, \u5800\u5149\u96c4. \u30c0\u30b5\u30c1\u30cb\u30d6\u3067\u8457\u540d\u306a\u4f4e\u5f62\u6210\u9ac4\u3092\u5448\u3057\u305f\u6162\u6027\u671f\u6162\u6027\u9aa8\u9ac4\u6027\u767d\u8840\u75c5\u306e\u4e00\u4f8b. \u7b2c77\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2015.<\/li>\n\n\n\n<li>Cho Y, Inada K, Koshino M, Okoshi Y, Hori M, Iijima T, Saito H, Kojima H. Contribution of hepatocyte growth factor (HGF) to angiogenesis in multiple myeloma. \u7b2c77\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2015.<\/li>\n\n\n\n<li>\u4e95\u53e3\u7814\u5b50, \u5c0f\u5cf6\u5bdb, \u5f35\u6109\u7d00\u5b50, \u6e0b\u8c37\u5f70, \u6e0b\u8c37\u548c\u5b50. \u764c\u60a3\u8005\u8840\u6e05\u306b\u304a\u3051\u308b\u53ef\u6eb6\u578bCD155\u767a\u73fe\u306e\u4e0a\u6607. \u7b2c74\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a, 2015.<\/li>\n\n\n\n<li>\u77f3\u9ed2\u613c\u543e, \u5800\u5149\u96c4, \u52a0\u5009\u4e95\u771f\u7d00, \u5c0f\u5cf6\u5bdb, \u4e09\u6a4b\u5f70\u4e00, \u85e4\u6fa4\u6587\u7d75, \u89d2\u7530\u76f4\u679d, \u8429\u539f\u654f\u4e4b, \u7b39\u6728\u65e5\u51fa\u7f8e, \u5927\u8d8a\u9756. \u5316\u5b66\u7642\u6cd5\u958b\u59cb\u524d\u306b\u672c\u6765\u3059\u3079\u304d\u6b6f\u79d1\u4ecb\u5165\u304c\u3067\u304d\u306a\u3044\u9020\u8840\u5668\u816b\u760d\u60a3\u8005\u306e\u53e3\u8154\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u3067\u5408\u4f75\u75c7\u3092\u8efd\u6e1b\u3059\u308b\u30b7\u30b9\u30c6\u30e0. \u7b2c13\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2015.<\/li>\n\n\n\n<li>\u52a0\u5009\u4e95\u771f\u7d00, \u77f3\u9ed2\u613c\u543e, \u5800\u5149\u96c4, \u5c0f\u5cf6\u5bdb, \u89d2\u7530\u76f4\u679d, \u8429\u539f\u654f\u4e4b, \u7b39\u6728\u65e5\u51fa\u7f8e. \u5e38\u52e4\u6b6f\u79d1\u533b\u304c\u3044\u306a\u3044\u75c5\u9662\u3067\u306e\u6b6f\u79d1\u4ecb\u5165\u306b\u3088\u308b\u8cea\u306e\u9ad8\u3044\u304c\u3093\u6cbb\u7642\u5b9f\u73fe\u306e\u65b9\u6cd5. \u7b2c13\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2015.<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c, \u5150\u5c71\u5065, \u5ca9\u4e95\u5065\u592a\u90ce, \u6c38\u7530\u535a\u4e4b, \u5c71\u5ca1\u6b63\u6cbb, \u5927\u95a2\u745e\u6cbb, \u85e4\u679d\u771f\u53f8, \u4e94\u982d\u4e09\u79c0, \u8352\u6728\u771e\u88d5, \u5c0f\u5cf6\u5bdb. \u5168\u8eab\u5316\u5b66\u7642\u6cd5\u7121\u52b9\u5f8c\u306e\u5927\u8178\u764c\u809d\u8ee2\u79fb\u306b\u5bfe\u3059\u308b\u809d\u52d5\u6ce8\u5316\u5b66\u7642\u6cd5. \u7b2c13\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2015.<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3, \u4e09\u6a4b\u5f70\u4e00, \u85e4\u6fa4\u6587\u7d75, \u77f3\u9ed2\u613c\u543e, \u5c0f\u5cf6\u5bdb. \u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u6295\u4e0e\u4e2d\u306b\u9593\u8cea\u6027\u80ba\u708e\u3092\u8a8d\u3081\u305f\u8853\u5f8c\u4e73\u764c\u306e\u4e00\u4f8b. \u7b2c13\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2015.<\/li>\n\n\n\n<li>Boku N, Katakami N, Fujita S, Oda K, Tauchi K, Nakata K, Shinozaki K, Okuno M, Kawai Y, Kikukawa H, Suzuki R, Nakazawa H, Kojima H, Mizutani M, Hara T, Yokota T, Suzuki Y, Narabayashi M. A phase II randomized, double-blind, placebo-controlled study to evaluate naldemedine for the treatment of opioid-induced constipation (OIC) in patients with cancer pain. ASCO Annual Meeting, 2015.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u9234\u6728\u5609\u6cbb, \u4e09\u6a4b\u5f70\u4e00, \u6b66\u4e95\u656c\u53f8, \u672c\u9593\u771f\u4eba. \u30e9\u30d1\u30c1\u30cb\u30d6\u306b\u3088\u308b\u9593\u8cea\u6027\u80ba\u708e\u306e\u75c7\u4f8b\u306b\u304a\u3051\u308b\u8840\u4e2d\u6fc3\u5ea6\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0. \u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2015.<\/li>\n\n\n\n<li>\u5c0f\u6cc9\u548c\u7f8e, \u5927\u795e\u6b63\u5b8f, \u5185\u85e4\u52a0\u5948\u5b50, \u5c71\u7530\u5e79\u5b50, \u9234\u6728\u4e00\u885b, \u83ca\u5730\u5343\u6625, \u6a2a\u5c71\u967d\u5b50, \u5c0f\u5cf6\u5bdb, \u77f3\u9ed2\u613c\u543e, \u6b66\u4e95\u656c\u53f8. \u5f53\u9662\u306b\u304a\u3051\u308b\u6297\u304c\u3093\u5264\u6c5a\u67d3\u306e\u5b9f\u614b\u8abf\u67fb. \u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2015.<\/li>\n\n\n\n<li>\u4e95\u5742\u90a6\u5f66, \u5927\u795e\u6b63\u5b8f, \u8c37\u4e2d\u6566\u7f8e, \u5c71\u4e0b\u771f\u4ee5, \u9234\u6728\u4e00\u885b, \u5ca9\u4e0a\u667a\u7f8e, \u93d1\u6728\u5b5d\u4e4b, \u6b66\u4e95\u656c\u53f8. \u65b0\u898f\u5206\u5b50\u6a19\u7684\u85ac\u30a2\u30ec\u30af\u30c1\u30cb\u30d6\u306b\u304a\u3051\u308b\u5f53\u9662\u85ac\u5264\u79d1\u306e\u53d6\u308a\u7d44\u307f\u306b\u3064\u3044\u3066. \u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u95a2\u6771\u30d6\u30ed\u30c3\u30af\u7b2c45\u56de\u5b66\u8853\u5927\u4f1a, 2015.<\/li>\n\n\n\n<li>\u5c71\u4e0b\u771f\u4ee5, \u5927\u795e\u6b63\u5b8f, \u8c37\u4e2d\u6566\u7f8e, \u5185\u85e4\u52a0\u5948\u5b50, \u4e95\u5742\u90a6\u5f66, \u5c71\u7530\u5e79\u5b50, \u5c0f\u6cc9\u548c\u7f8e, \u9234\u6728\u4e00\u885b, \u5ca9\u4e0a\u667a\u7f8e, \u6b66\u4e95\u656c\u53f8. \u7d4c\u53e3\u6297\u304c\u3093\u5264\u9069\u6b63\u4f7f\u7528\u306e\u305f\u3081\u306e\u60a3\u8005\u60c5\u5831\u6d3b\u7528\u306b\u4fc2\u308b\u8abf\u67fb. \u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u95a2\u6771\u30d6\u30ed\u30c3\u30af\u7b2c45\u56de\u5b66\u8853\u5927\u4f1a, 2015.<\/li>\n\n\n\n<li>Ogami M, Suzuki Y, Naito K, Yamada M, Kaburagi T, Uchiumi K, Yamada Y, Takei K, Homma M. Co-administration of proton pump inhibitor decreases plasma concentration of erlotinib in patients with non-small cell lung cancer. 14th International Congress of Therapeutic Drug Monitoring &amp; Clinical Toxicology, 2015.<\/li>\n\n\n\n<li>\u5742\u672c\u6893, \u9ad8\u7530\u6e05\u5b50. \u5316\u5b66\u7642\u6cd5\u306b\u4f34\u306a\u3046\u53e3\u8154\u7c98\u819c\u708e\u306b\u5bfe\u3059\u308b\u770b\u8b77\u5e2b\u306e\u610f\u8b58\u8abf\u67fb. \u7b2c24\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a, 2015.<\/li>\n\n\n\n<li>\u6a2a\u5c71\u967d\u5b50, \u5c0f\u6797\u7531\u9999. \u5927\u8178\u764c\u60a3\u8005\u306eEGFR\u963b\u5bb3\u85ac\u306b\u3088\u308bQOL\u3068\u76ae\u819a\u969c\u5bb3\u306e\u95a2\u9023\u6027\u306e\u691c\u8a0e. \u7b2c16\u56de\u65e5\u672c\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u5b66\u4f1a\u8328\u57ce\u770c\u652f\u90e8\u5b66\u8853\u5927\u4f1a, 2015.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2014\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Inada K, Okoshi Y, Cho Y, Saito H, Iijima T, Hori M, Kojima H. Availability of circulating microRNAs as a biomarker for early diagnosis of diffuse large B-cell lymphoma. 56th annual meeting of the American Society of Hematology, 2014.<\/li>\n\n\n\n<li>Okoshi Y, Koshino M, Hayashi Y, Tamaki Y, Kojima H, Hori M. R-CHOP\/CHOP-like regimen plus radiotherapy for DLBCL with bulky disease. -a single center experience- \u7b2c76\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2014.<\/li>\n\n\n\n<li>Hori M, Okoshi Y, Koshino M, Kojima H, Fife N, Iha H. Specification of the LGI is valued as a key maker for MM response to lenalidomide treatment. \u7b2c76\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2014.<\/li>\n\n\n\n<li>Inada K, Okoshi Y, Cho Y, Iijima T, Kojima H. Comparison of microRNA expression levels obtained from serum, exosome-enriched serum, and tumor tissue in DLBCL patients. \u7b2c73\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2014.<\/li>\n\n\n\n<li>\u9ad8\u7530\u6e05\u5b50, \u83ca\u5730\u5343\u6625, \u6a2a\u5c71\u967d\u5b50, \u9234\u6728\u6bd4\u5442\u7f8e. \u5916\u6765\u5316\u5b66\u7642\u6cd5\u3092\u53d7\u3051\u308b\u60a3\u8005\u306e\u30bb\u30eb\u30d5\u30b1\u30a2\u884c\u52d5\u3092\u4fc3\u3059\u95a2\u9023\u8981\u56e0. \u7b2c23\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a, 2014\u5e742\u6708.<\/li>\n\n\n\n<li>\u5de5\u85e4\u5927\u8f14, \u5927\u6a4b\u4e00\u8f1d, \u7c73\u91ce\u7422\u54c9, \u4e2d\u6751\u88d5\u4e00, \u54c1\u5ddd\u7be4\u53f8, \u57a3\u82b1\u548c\u5f66, \u5c0f\u6797\u6b66, \u5409\u7530\u8fd1\u601d, \u6842\u884c\u5b5d, \u592a\u7530\u80b2\u4ee3, \u65b0\u4e95\u6587\u5b50, \u52a0\u85e4\u6df3, \u5c71\u672c\u6643, \u8c4a\u7530\u8302\u96c4, \u718a\u8c37\u9686\u5fd7, \u5ddd\u4e95\u4fe1\u5b5d, \u4e09\u6728\u5fb9, \u5927\u548c\u7530\u5553, \u5c0f\u5cf6\u5bdb, \u5742\u5dfb\u58fd. \u672a\u6cbb\u7642\u591a\u767a\u6027\u9aa8\u9ac4\u816b\u306b\u5bfe\u3059\u308bVAD\u7642\u6cd5\u5148\u884cBD\u7642\u6cd5\uff0b\u81ea\u5bb6\u672b\u68a2\u8840\u5e79\u7d30\u80de\u79fb\u690d\u306e\u591a\u65bd\u8a2d\u5171\u540c\u7b2c2\u76f8\u81e8\u5e8a\u8a66\u9a13. \u7b2c36\u56de\u65e5\u672c\u9020\u8840\u7d30\u80de\u79fb\u690d\u5b66\u4f1a\u7dcf\u4f1a, 2014\u5e743\u6708.<\/li>\n\n\n\n<li>\u963f\u90e8\u6afb\u5b50, \u5927\u795e\u6b63\u5b8f, \u8597\u90e8\u6843\u4ee3, \u4f50\u85e4\u5e78\u88d5, \u83ca\u5730\u5343\u6625, \u5c0f\u5cf6\u5bdb, \u6b66\u4e95\u656c\u53f8. \u4e2d\u7b49\u5ea6\u50ac\u5410\u6027\u30ea\u30b9\u30af\u6297\u304c\u3093\u5264\u6295\u4e0e\u60a3\u8005\u306b\u304a\u3051\u308bCTCAE\u3068MAT\u3092\u7528\u3044\u305f\u60aa\u5fc3\u30fb\u5614\u5410\u306e\u8a55\u4fa1\u306b\u5bfe\u3059\u308b\u6bd4\u8f03\u691c\u8a0e. \u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2014\u5e743\u6708.<\/li>\n\n\n\n<li>\u4f50\u85e4\u5e78\u88d5, \u5927\u795e\u6b63\u5b8f, \u963f\u90e8\u6afb\u5b50, \u9577\u7530\u6566\u7f8e, \u8597\u90e8\u6843\u4ee3, \u5c0f\u6cc9\u548c\u7f8e, \u9234\u6728\u4e00\u885b, \u83ca\u5730\u5343\u6625, \u5c0f\u5cf6\u5bdb, \u6b66\u4e95\u656c\u53f8. \u5927\u8178\u764c\u306b\u304a\u3051\u308bFOLFIRI\u7642\u6cd5\u306e\u60aa\u5fc3\u5614\u5410\u8abf\u67fb. \u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2014\u5e743\u6708.<\/li>\n\n\n\n<li>\u8597\u90e8\u6843\u4ee3, \u5927\u795e\u6b63\u5b8f, \u9577\u7530\u6566\u7f8e, \u9ad8\u7530\u6e05\u5b50, \u5742\u672c\u6893, \u83ca\u5730\u5343\u6625, \u5c0f\u5cf6\u5bdb, \u6b66\u4e95\u656c\u53f8. \u30ec\u30b4\u30e9\u30d5\u30a7\u30cb\u30d6\u5c0e\u5165\u6642\u306e\u53d6\u308a\u7d44\u307f\u3068\u526f\u4f5c\u7528\u767a\u73fe\u72b6\u6cc1. \u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2014\u5e743\u6708.<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3, \u5929\u8c9d\u8ce2\u4e8c, \u4eca\u897f\u771f\u7f8e\u5b50, \u5927\u95a2\u745e\u6cbb, \u85e4\u679d\u771f\u53f8, \u8352\u6728\u771e\u88d5, \u4e94\u982d\u4e09\u79c0, \u85e4\u6fa4\u6587\u7d75, \u4e09\u6a4b\u5f70\u4e00, \u5c0f\u5cf6\u5bdb. \u5f53\u9662\u306b\u304a\u3051\u308b75\u6b73\u4ee5\u4e0a\u9ad8\u9f62\u8005\u80c3\u764c\u8853\u5f8c\u88dc\u52a9\u5316\u5b66\u7642\u6cd5\u306e\u73fe\u72b6. \u7b2c100\u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u7dcf\u4f1a, 2014\u5e744\u6708.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u5c0f\u5cf6\u5bdb, \u6b66\u4e95\u656c\u53f8. Analysis of risk factoe for hypersensitivity reaction in oxaliplatin reintroduced patients. \u7b2c12\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a, 2014\u5e747\u6708.<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3, \u4eca\u897f\u771f\u7f8e\u5b50, \u5927\u95a2\u745e\u6cbb, \u85e4\u679d\u771f\u53f8, \u8352\u6728\u771e\u88d5, \u5929\u8c9d\u8ce2\u4e8c, \u4e94\u982d\u4e09\u79c0, \u85e4\u6fa4\u6587\u7d75, \u4e09\u6a4b\u5f70\u4e00, \u5c0f\u5cf6\u5bdb. A present status of chemotherapy with elderly advanced gastric cancer in Ibaraki Prefectural Central Hospital. \u7b2c12\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a, 2014\u5e747\u6708.<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3, \u85e4\u679d\u771f\u53f8, \u4eca\u897f\u771f\u7f8e\u5b50, \u5927\u95a2\u745e\u6cbb, \u85e4\u6fa4\u6587\u7d75, \u8352\u6728\u771e\u88d5, \u5929\u8c9d\u8ce2\u4e8c, \u4e94\u982d\u4e09\u79c0, \u4e09\u6a4b\u5f70\u4e00, \u6589\u85e4\u4ec1\u662d, \u98ef\u5cf6\u9054\u592b, \u5c0f\u5cf6\u5bdb. EUS-FNA\u3067\u8a3a\u65ad\u3057\u3048\u305f\u98df\u9053\u764c\u7570\u6642\u6027\u5b64\u7acb\u6027\u81b5\u8ee2\u79fb\u306e\u4e00\u4f8b. \u7b2c52\u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2014\u5e748\u6708.<\/li>\n\n\n\n<li>Ohgami M, Homma M, Suzuki Y, Mitsuhashi S, Fujisawa F, Kaburagi T, Uchiumi K, Yamada Y, Bando H, Hara H, Takei K. A simple high-performance liquid chromatography for determining lapatinib and erlotinib in human plasma. \u7b2c29\u56de\u65e5\u672c\u85ac\u7269\u52d5\u614b\u5b66\u4f1a\u5408\u540c\u5e74\u4f1a, 2014\u5e7410\u6708.<\/li>\n\n\n\n<li>\u5c71\u4e0b\u771f\u4ee5, \u5927\u795e\u6b63\u5b8f, \u8c37\u4e2d\u6566\u7f8e, \u5185\u85e4\u52a0\u5948\u5b50, \u4e95\u5742\u90a6\u5f66, \u5c71\u7530\u5e79\u5b50, \u5c0f\u6cc9\u548c\u7f8e, \u9234\u6728\u4e00\u885b, \u5ca9\u4e0a\u667a\u7f8e, \u6b66\u4e95\u656c\u53f8. \u7d4c\u53e3\u6297\u304c\u3093\u5264\u9069\u6b63\u4f7f\u7528\u306e\u305f\u3081\u306e\u60a3\u8005\u60c5\u5831\u6d3b\u7528\u306b\u4fc2\u308b\u30a2\u30f3\u30b1\u30fc\u30c8\u8abf\u67fb. \u7b2c25\u56de\u8328\u57ce\u770c\u85ac\u5264\u5e2b\u5b66\u8853\u5927\u4f1a, 2014\u5e7411\u6708.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2013\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u83ca\u5730\u5343\u6625, \u7cf8\u8cc0\u667a\u5b50. \u5f53\u9662\u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u306b\u304a\u3051\u308b\u96fb\u8a71\u76f8\u8ac7\u306e\u73fe\u72b6\u3068\u4eca\u5f8c\u306e\u8ab2\u984c. \u7b2c22\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a, 2013\u5e742\u6708, \u8328\u57ce.<\/li>\n\n\n\n<li>\u85e4\u6fa4\u6587\u7d75, \u68ee\u4e0b\u4e9c\u5e0c\u5b50, \u5e73\u91ce\u7a14. \u5f53\u9662\u306b\u304a\u3051\u308b\u5c40\u6240\u9032\u884cT4\u4e73\u764c\u75c7\u4f8b\u306e\u691c\u8a0e. \u7b2c21\u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013\u5e746\u6708, \u9759\u5ca1<\/li>\n\n\n\n<li>\u85e4\u6fa4\u6587\u7d75, \u98ef\u585a\u8061\u4ecb, \u4e09\u6a4b\u5f70\u4e00, \u5800\u5149\u96c4, \u93d1\u6728\u5b5d\u4e4b, \u5929\u8c9d\u8ce2\u4e8c, \u5927\u8d8a\u9756, \u68ee\u4e0b\u4e9c\u5e0c\u5b50, \u5c0f\u5cf6\u5bdb. \u5f53\u9662\u306b\u304a\u3051\u308b\u539f\u767a\u4e0d\u660e\u764c\u306b\u3064\u3044\u3066\u306e\u5f8c\u65b9\u8996\u7684\u691c\u8a0e. \u7b2c11\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2013\u5e748\u6708, \u4ed9\u53f0<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0c\u5c0f\u5cf6\u5bdb\uff0c\u963f\u90e8\u6afb\u5b50\uff0c\u8597\u90e8\u6843\u4ee3\uff0c\u83ca\u5730\u5343\u6625\uff0c\u7cf8\u8cc0\u667a\u5b50\uff0c\u5cf6\u7530\u5321\u5f66. EGFR\u963b\u5bb3\u85ac\u306b\u3088\u308b\u76ae\u819a\u969c\u5bb3\u306b\u5bfe\u3059\u308b\u5916\u7528\u5264\u306e\u4e88\u9632\u7684\u6295\u4e0e\u306e\u6709\u52b9\u6027. \u7b2c11\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2013\u5e748\u6708\uff0c\u4ed9\u53f0<\/li>\n\n\n\n<li>\u5c71\u5ca1\u6b63\u6cbb, \u5929\u8c9d\u8ce2\u4e8c, \u5927\u95a2\u745e\u6cbb, \u77f3\u6a4b\u8087, \u85e4\u679d\u771f\u53f8, \u4e94\u982d\u4e09\u79c0, \u8352\u6728\u771e\u88d5, \u98ef\u585a\u8061\u4ecb, \u85e4\u6fa4\u6587\u7d75, \u5c0f\u5cf6\u5bdb. \u5207\u9664\u4e0d\u80fd\u9032\u884c\u30fb\u518d\u767a\u5927\u8178\u764c\u306e\u4e8c\u6b21\u6cbb\u7642\u306b\u304a\u3051\u308b\u5206\u5b50\u6a19\u7684\u7642\u6cd5\u306e\u691c\u8a0e. \u7b2c11\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2013\u5e748\u6708, \u4ed9\u53f0<\/li>\n\n\n\n<li>Cho Y, Kojima H. Prediction of therapeutic efficacy by measuring circulating Bmab-unconjugated VEGF-A in recurrent or metastatic CRC. \u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013\u5e7410\u6708, \u6a2a\u6d5c<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0c\u83ca\u5730\u5343\u6625\uff0c\u7cf8\u8cc0\u667a\u5b50\uff0c\u5c0f\u5cf6\u5bdb\uff0c\u6b66\u4e95\u656c\u53f8. \u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u5229\u7528\u60a3\u8005\u306b\u304a\u3051\u308b\u6e80\u8db3\u5ea6\u8abf\u67fb. \u7b2c52\u56de\u5168\u56fd\u81ea\u6cbb\u4f53\u75c5\u9662\u5b66\u4f1a\uff0c2013\u5e7410\u6708\uff0c\u4eac\u90fd<\/li>\n\n\n\n<li>\u85e4\u6fa4\u6587\u7d75, \u98ef\u585a\u8061\u4ecb, \u83c5\u8c37\u660e\u5fb3, \u5927\u95a2\u745e\u6cbb, \u85e4\u679d\u771f\u53f8, \u8352\u6728\u771e\u88d5, \u5929\u8c9d\u8ce2\u4e8c, \u5c0f\u5cf6\u5bdb, \u5927\u795e\u6b63\u5b8f. \uff4dFOLFOX6\/FOLFIRI\u306b\u304a\u3051\u308bG-CSF\u4f7f\u7528\u306e\u691c\u8a0e. \u7b2c51\u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2013\u5e7410\u6708, \u4eac\u90fd<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2012\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Cho Y, Hori M, Okoshi Y, Yuasa H, Komeno T, Yoshida C, Katsura Y, Ota I, Shimizu S, Kamoshita M, Sasaki K, Tanaka K, Mukai H, Kojima H. Prediction of bortezomib-induced severe neurologic events by monitoring proteasome activity in PBMC. \u7b2c74\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2012.<\/li>\n\n\n\n<li>Yuasa H, Hori M, Meshituka S, Okoshi Y, Mitsuhashi S, Kojima H. The response to azacytidine in high-risk myelodysplastic syndrome. \u7b2c74\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2012.<\/li>\n\n\n\n<li>Shinagawa A, Kudo D, Komeno T, Yoshida C, Katsura Y, Ota I, Shimizu S, Kamoshita M, Meshituka S, Hori M, Okoshi Y, Yuasa H, Kojima H. A phase I study of weekly bortezomib for Japanese patients with recurrent and refractory myeloma. \u7b2c74\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2012.<\/li>\n\n\n\n<li>\u6e6f\u6d45\u535a\u7f8e, \u5c0f\u5cf6\u5bdb, \u98ef\u585a\u8061\u4ecb, \u68ee\u4e0b\u4e9c\u5e0c\u5b50, \u4e09\u6a4b\u5f70\u4e00. \u5927\u8178\u764c\u5316\u5b66\u7642\u6cd5\u4e2d\u306b\u767a\u75c7\u3057\u305f\u6cbb\u7642\u95a2\u9023\u9aa8\u9ac4\u7570\u5f62\u6210\u75c7\u5019\u7fa4\u306e1\u4f8b. \u7b2c10\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2012.<\/li>\n\n\n\n<li>\u592a\u7530\u660c\u4e00\u90ce, \u6797\u7f8e\u4ee3\u5b50, \u8cb4\u5cf6\u7ae0\u5fb3, \u548c\u7530\u5c06\u6804, \u5b97\u50cf\u5468\u4e8c, \u6e21\u908a\u7d75\u7f8e, \u5b89\u91ce\u4f38\u6d69, \u5c0f\u5cf6\u5bdb. mFOLFOX6\u65bd\u884c\u4e2d\u306b\u767a\u75c7\u3057\u305f\u6bd4\u8f03\u7684\u7a00\u306a\u6709\u5bb3\u4e8b\u8c61\u306e\u691c\u8a0e. \u7b2c10\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2012.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u7cf8\u8cc0\u667a\u5b50, \u83ca\u5730\u5343\u6625, \u5c0f\u5cf6\u5bdb, \u5cf6\u7530\u5321\u5f66. \u30aa\u30ad\u30b5\u30ea\u30d7\u30e9\u30c1\u30f3\u306b\u3088\u308b\u904e\u654f\u53cd\u5fdc\u306b\u95a2\u3059\u308b\u5f8c\u65b9\u8996\u7684\u8abf\u67fb. \u7b2c10\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2012.<\/li>\n\n\n\n<li>Cho Y, Hori M, Okoshi Y, Komeno T, Yoshida C, Katsura Y, Ota I, Shinagawa A, Kudo D, Shimizu S, Sasaki K, Tanaka K, Mukai H, Kojima H, Ibaraki Hematology Oncology Palliation Expert Meeting. Predicting bortezomib-related severe neurologic adverse events by measuring proteasome activity in PBMCs. ASCO Annual Meeting, 2012.<\/li>\n\n\n\n<li>\u7cf8\u8cc0\u667a\u5b50, \u83ca\u5730\u5343\u6625. \u5316\u5b66\u7642\u6cd5\u306b\u3088\u308b\u76ae\u819a\u969c\u5bb3\u306b\u5bfe\u3059\u308b\u30bb\u30eb\u30d5\u30b1\u30a2\u652f\u63f4\u306e\u691c\u8a0e. \u7b2c21\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a 2012\u5e742\u6708, \u8328\u57ce.<\/li>\n\n\n\n<li>\u6728\u6751\u76f4\u7f8e, \u91ce\u672c\u5948\u7f8e, \u5742\u672c\u6893, \u7cf8\u8cc0\u667a\u5b50. \u5916\u6765\u5316\u5b66\u7642\u6cd5\u306b\u304a\u3051\u308b\u60a3\u8005, \u5bb6\u65cf\u3092\u542b\u3081\u305f\u533b\u7642\u9023\u643a\u306e\u3042\u308a\u65b9. \u7b2c13\u56de\u65e5\u672c\u533b\u7642\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u5b66\u4f1a, \u8328\u57ce\u770c\u652f\u90e8\u5b66\u8853\u96c6\u4f1a. 2012\u5e748\u6708, \u8328\u57ce.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u8597\u90e8\u6843\u4ee3, \u5cf6\u7530\u5321\u5f66. \u30b7\u30af\u30ed\u30db\u30b9\u30d5\u30a1\u30df\u30c9\u6295\u4e0e\u60a3\u8005\u306b\u304a\u3051\u308b\u30a2\u30eb\u30b3\u30fc\u30eb\u6442\u53d6\u91cf\u53ca\u3073\u30a2\u30eb\u30b3\u30fc\u30eb\u4ee3\u8b1d\u80fd\u529b\u304c\u98df\u6b32\u4e0d\u632f\u306b\u4e0e\u3048\u308b\u5f71\u97ff. \u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u95a2\u6771\u30d6\u30ed\u30c3\u30af\u7b2c42\u56de\u5b66\u8853\u5927\u4f1a, 2012\u5e748\u6708, \u6a2a\u6d5c.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u690d\u6728\u3072\u3068\u307f, \u8597\u90e8\u6843\u4ee3, \u963f\u90e8\u6afb\u5b50, \u5cf6\u7530\u5321\u5f66. Pemetrexed\u306e\u76ae\u75b9\u767a\u73fe\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c33\u56de\u65e5\u672c\u81e8\u5e8a\u85ac\u7406\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.11\u6708, \u6c96\u7e04.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2011\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Cho Y, Ota S, Hori M, Yuasa H, Komeno T, Yoshida C, Katsura Y, Shimizu S, Kamoshita M, Sasaki K, Tanaka K, Mukai H, Kojima H. Measurement of proteasome activity for predicting severe adverse events caused by bortezomib. \u7b2c73\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2011.<\/li>\n\n\n\n<li>Ohta S, Cho Y, Nagai K, Uchida Y, Shibata M, Nogami T, Doi M, Iijima T, Saitoh H, Mitsuhashi S, Hori M, Kojima H. Feasibility for introducing molecular targeting therapy for the treatment of cancer of unknown primary by analyzing intracellular signaling molecules. \u7b2c9\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2011.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u9752\u5c71\u4e00\u7d00, \u8597\u90e8\u6843\u4ee3, \u83ca\u5730\u5343\u6625, \u6a2a\u5c71\u967d\u5b50, \u9ad8\u7530\u6e05\u5b50, \u5c0f\u6797\u7531\u9999, \u7cf8\u8cc0\u667a\u5b50, \u91ce\u672c\u5948\u7f8e, \u5742\u672c\u6893, \u4e09\u6a4b\u5f70\u4e00, \u6e6f\u6d45\u535a\u7f8e, \u68ee\u4e0b\u4e9c\u5e0c\u5b50, \u98ef\u585a\u8061\u4ecb, \u5c0f\u5cf6\u5bdb, \u5cf6\u7530\u5321\u5f66. \u5916\u6765\u5316\u5b66\u7642\u6cd5\u306b\u304a\u3051\u308b\u91cd\u7be4\u306a\u6709\u5bb3\u4e8b\u8c61\u306e\u767a\u73fe\u72b6\u6cc1.\u3000\u7b2c12\u56de\u65e5\u672c\u533b\u7642\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u5b66\u4f1a\u3000\u8328\u57ce\u770c\u652f\u90e8\u5b66\u8853\u96c6\u4f1a,\u30002011\u5e7411\u6708\u3000\u8328\u57ce<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2010\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u5927\u795e\u6b63\u5b8f, \u4e09\u6a4b\u5f70\u4e00, \u9ed2\u6fa4\u514b\u6a39, \u8c37\u4e2d\u6566\u7f8e, \u83ca\u5730\u5343\u6625, \u6a2a\u5c71\u967d\u5b50, \u9ad8\u7530\u6e05\u5b50, \u5c0f\u6797\u7531\u9999, \u6c38\u5cf6\u5948\u6d25\u5b50, \u7cf8\u8cc0\u667a\u5b50, \u6d77\u85e4\u4f73\u4ee3\u5b50, \u5cf6\u7530\u5321\u5f66, \u6c38\u4e95\u516c\u6d0b, \u5c0f\u5cf6\u5bdb. \u4e73\u304c\u3093\u8853\u524d\u8853\u5f8c\u88dc\u52a9\u5316\u5b66\u7642\u6cd5\uff08EC\uff09\u306b\u304a\u3051\u308b\u6709\u5bb3\u4e8b\u8c61\u306e\u89e3\u6790. \u7b2c8\u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u7dcf\u4f1a. 2010\u5e743\u6708, \u6771\u4eac.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f, \u9752\u5c71\u4e00\u7d00, \u5cf6\u7530\u3000\u5321\u5f66\uff0eEC\u7642\u6cd5\u306b\u304a\u3051\u308b\u30a2\u30d7\u30ec\u30d4\u30bf\u30f3\u30c8\u306e\u6709\u52b9\u6027\uff0e\u7b2c20\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a\u30002010\u5e7411\u6708, \u5343\u8449<\/li>\n\n\n\n<li>\u9752\u5c71\u4e00\u7d00, \u5927\u795e\u6b63\u5b8f, \u67f4\u7530\u7f8e\u4e5f\u5b50, \u8c37\u4e2d\u6566\u7f8e, \u9ed2\u6fa4\u514b\u6a39, \u5cf6\u7530\u3000\u5321\u5f66. \u50ac\u5410\u30ea\u30b9\u30af\u4e2d\u7b49\u5ea6\u306e\u5316\u5b66\u7642\u6cd5\u306b\u304a\u3051\u308b\u30a2\u30d7\u30ec\u30d4\u30bf\u30f3\u30c8\u4f7f\u7528\u6642\u306b\u767a\u751f\u3057\u305f\u6709\u5bb3\u4e8b\u8c61\u306b\u3064\u3044\u3066. \u7b2c20\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a\u30002010\u5e7411\u6708, \u5343\u8449<\/li>\n\n\n\n<li>\u6a2a\u5c71\u967d\u5b50, \u9ad8\u7530\u6e05\u5b50, \u7cf8\u8cc0\u667a\u5b50, \u9234\u6728\u6bd4\u5442\u7f8e, \u83ca\u5730\u5343\u6625. \u5916\u6765\u5316\u5b66\u7642\u6cd5\u306b\u304a\u3051\u308b\u770b\u8b77\u306e\u5b89\u5168\u5bfe\u7b56. \u7b2c11\u56de\u65e5\u672c\u533b\u7642\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u5b66\u4f1a, \u8328\u57ce\u770c\u652f\u90e8\u5b66\u8853\u96c6\u4f1a. 2010\u5e7411\u6708, \u8328\u57ce.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2009\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u5927\u795e\u6b63\u5b8f, \u9ed2\u6fa4\u514b\u5df1, \u5c0f\u5cf6\u5bdb, \u5cf6\u7530\u5321\u5f66. \u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u306b\u304a\u3051\u308b\u85ac\u5264\u5e2b\u306e\u53d6\u308a\u7d44\u307f\u306b\u3064\u3044\u3066. \u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a. 2009\u5e749\u6708.<\/li>\n<\/ol>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-pb-accordion-item c-accordion__item js-accordion-item no-js\" data-initially-open=\"false\" data-click-to-close=\"true\" data-auto-close=\"true\" data-scroll=\"false\" data-scroll-offset=\"0\"><h2 id=\"at-1612\" class=\"c-accordion__title js-accordion-controller\" role=\"button\">III. \u305d\u306e\u4ed6<\/h2><div id=\"ac-1612\" class=\"c-accordion__content\">\n<h4 class=\"wp-block-heading\">2025\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u77f3\u9ed2\u613c\u543e\u300c\u3044\u307e\u3055\u3089\u805e\u3051\u306a\u3044\u304c\u3093\u30b2\u30ce\u30e0\u533b\u7642\uff08\u57fa\u790e\u7de8\uff09\u3053\u306e\u7814\u4fee\uff11\u56de\u3067\u3001\u3068\u308a\u3042\u3048\u305a\u6642\u4ee3\u306b\u8ffd\u3044\u3064\u3053\u3046\u300d \u304c\u3093\u533b\u7642\u5f93\u4e8b\u8005\u7814\u4fee\u4f1a2025. 1 (\u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662 Web)<\/li>\n\n\n\n<li>\u77f3\u9ed2\u613c\u543e\u300c\u660e\u65e5\u304b\u3089\u3067\u304d\u308b\u300c\u304c\u3093\u30b2\u30ce\u30e0\u533b\u7642\u300d \u304c\u3093\u30b2\u30ce\u30e0\u533b\u7642\u6982\u8ad6\u300d \u304c\u3093\u30b2\u30ce\u30e0\u51fa\u524d\u8b1b\u5ea7 2025. 1\uff08\u5c0f\u5c71\u8a18\u5ff5\u75c5\u9662\uff09<\/li>\n\n\n\n<li>\u77f3\u9ed2\u613c\u543e\u300c\u304c\u3093\u30b2\u30ce\u30e0\u533b\u7642\u300d \u770c\u653f\u51fa\u524d\u8b1b\u5ea7 2025.3 (\u6c34\u6238\u5e02\u6c11\u4f1a\u9928)<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2024\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u83c5\u8c37\u660e\u5fb3 Erbitux Academic cutting-edge lecture\u300c\u6297 EGFR \u6297\u4f53\u306e\u526f\u4f5c\u7528\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u306b\u3064\u3044\u3066\u300d2024.4 \uff08Web\uff09<\/li>\n\n\n\n<li>\u77f3\u9ed2\u613c\u543e\u300c\u660e\u65e5\u304b\u3089\u3067\u304d\u308b\u300c\u304c\u3093\u30b2\u30ce\u30e0\u533b\u7642\u300d\u304c\u3093\u30b2\u30ce\u30e0\u533b\u7642\u6982\u8ad6\u300d \u304c\u3093\u30b2\u30ce\u30e0\u51fa\u524d\u8b1b\u5ea7 2024.5\uff08\u6c34\u6238\u6e08\u751f\u4f1a\u75c5\u9662\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3 GI cancer Chemotherapy Meeting 2024 in Mito\u300c\u304c\u3093\u30b2\u30ce\u30e0\u691c\u67fb\u4f53\u5236\u306b\u3064\u3044\u3066\u300d2024.5\uff08Web\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3 \u98df\u9053\u764c\u30aa\u30d7\u30b8\u30fc\u30dcWeb lecture 2024.6\uff08Web\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3 ILD Management Web Seminar \uff5e\u85ac\u5264\u6027\u80ba\u969c\u5bb3\u306b\u3064\u3044\u3066\u8003\u3048\u308b\uff5e 2024.7\uff08Web\uff09<\/li>\n\n\n\n<li>\u77f3\u9ed2\u613c\u543e\u300c\u9662\u5185\u5916\u306e\u30c1\u30fc\u30e0\u3067\u652f\u3048\u308b\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u306e\u526f\u4f5c\u7528\u5bfe\u7b56\u300dimAE Team Management Seminar 2024.9 (Web)<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3 \u98df\u9053\u764c Hybrid Web Seminar\uff5e\u9032\u884c\u518d\u767a\u98df\u9053\u304c\u3093\u306e\u85ac\u7269\u7642\u6cd5\u306b\u304a\u3051\u308b Clinical Question\uff5e 2024.9 \uff08Web\uff09<\/li>\n\n\n\n<li>\u77f3\u9ed2\u613c\u543e\u300c\u306a\u305c\u3001\u304c\u3093\u306f\u65e9\u671f\u767a\u898b\u30fb\u65e9\u671f\u6cbb\u7642\u304c\u671b\u307e\u3057\u3044\u306e\u304b\uff1f\u304c\u3093\u306b\u306a\u3063\u3066\u304b\u3089\u306e\u3053\u3068\u3092\u3088\u304f\u77e5\u308c\u3070\u308f\u304b\u308a\u307e\u3059\u3002\u300d R6 \u5e74\u5ea6\u304c\u3093\u4e88\u9632\u63a8\u9032\u54e1\u990a\u6210\u8b1b\u7fd2\u4f1a 2024.11\uff08\u3064\u304f\u3070\u5e02\uff09<\/li>\n\n\n\n<li>\u77f3\u9ed2\u613c\u543e\u300c\u306a\u305c\u3001\u304c\u3093\u306f\u65e9\u671f\u767a\u898b\u30fb\u65e9\u671f\u6cbb\u7642\u304c\u671b\u307e\u3057\u3044\u306e\u304b\uff1f\u304c\u3093\u306b\u306a\u3063\u3066\u304b\u3089\u306e\u3053\u3068\u3092\u3088\u304f\u77e5\u308c\u3070\u308f\u304b\u308a\u307e\u3059\u3002\u300d R6 \u5e74\u5ea6\u304c\u3093\u4e88\u9632\u63a8\u9032\u54e1\u990a\u6210\u8b1b\u7fd2\u4f1a 2024.12\uff08\u6c34\u6238\u5e02\uff09<\/li>\n\n\n\n<li> \u77f3\u9ed2\u613c\u543e\u300cICI \u306e\u526f\u4f5c\u7528\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0,\u30ec\u30b8\u30e1\u30f3\u7ba1\u7406-\u85ac\u5264\u5e2b,\u533b\u5e2b\u306e\u305d\u308c\u305e\u308c\u306e\u7acb\u5834\u304b\u3089-\u300d Immuno Oncology Pharmacy Seminar 2024.12\uff08Web\uff09<\/li>\n\n\n\n<li> \u5927\u795e\u6b63\u5b8f\u3000\u6297\u304c\u3093\u85ac\u306f\u3061\u3087\u3063\u3068\u5927\u5909!?\uff5e\u30d0\u30a4\u30aa\u30b7\u30df\u30e9\u30fc\u5c0e\u5165\u306e\u5b9f\u969b\uff5e\u7b2c 26 \u56de\u65e5\u672c\u533b\u85ac\u54c1\u60c5\u5831\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a \u30e1\u30c7\u30a3\u30ab\u30eb\u30bb\u30df\u30ca\u30fc\u30002024.6\uff08\u5343\u8449\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\u3000\u304c\u3093\u85ac\u7269\u7642\u6cd5\u306e\u5b89\u5168\u7ba1\u7406\uff0e\u591a\u5730\u70b9\u5408\u540c\u30e1\u30c7\u30a3\u30ab\u30eb\u30fb\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b92024.11\uff08WEB\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\u3000ICI \u526f\u4f5c\u7528\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u3001\u30ec\u30b8\u30e1\u30f3\u7ba1\u7406\u3000Immuno-Oncology Pharmacy Seminar\u30002024.12\uff08WEB\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\u3000\u5f53\u9662\u306b\u304a\u3051\u308birAE \u5bfe\u7b56\u3000LC Seminar\u30002025.2\uff08WEB\uff09<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2023\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u83c5\u8c37\u660e\u5fb3. \u98df\u9053\u764c\u4e00\u6b21\u6cbb\u7642\u306e\u6700\u9069\u306a\u85ac\u7269\u7642\u6cd5\u3092\u8003\u3048\u308b. <br>\u98df\u9053\u764cClinical Practice Seminar\uff08\u30b3\u30e1\u30f3\u30c6\u30fc\u30bf\u30fc\uff09, 2023.3\uff08Web\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f. \u5f53\u9662\u306b\u304a\u3051\u308birAE\u306b\u5bfe\u3059\u308b\u85ac\u5264\u5e2b\u306e\u53d6\u308a\u7d44\u307f.\u3000<br>Immuno-Oncology Seminar in \u8328\u57ce, &nbsp;2023.2\uff08WEB\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f. irAE\u306b\u85ac\u5264\u5e2b\u304c\u3069\u306e\u3088\u3046\u306b\u95a2\u308f\u3063\u3066\u304d\u305f\u304b.\u3000<br>\u7b2c11\u56de\u770c\u5357\u30fb\u770c\u897f\u304c\u3093\u5c02\u9580\u8a8d\u5b9a\u85ac\u5264\u5e2b\u30bb\u30df\u30ca\u30fc, 2023.2\uff08WEB\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f. \u85ac\u5264\u5e2b\u304b\u3089\u307f\u305f\u5916\u6765\u5316\u5b66\u7642\u6cd5\u5ba4\u306e\u52b9\u7387\u7684\u306a\u904b\u7528<br>GAIRAI seminar \u2013\u5916\u6765\u5316\u5b66\u7642\u6cd5\u904b\u7528\u52b9\u7387\u5316\u306e\u305f\u3081\u306e\u30bb\u30df\u30ca\u30fc\u2013, 2023.6\uff08WEB\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f. \u304c\u3093\u30b2\u30ce\u30e0\u533b\u7642\u306b\u5bfe\u3059\u308b\u85ac\u5264\u5e2b\u306e\u95a2\u308f\u308a<br>\u8328\u57ce\u770c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a Oncology Pharmacist Seminar vol.3, 2023.7\uff08WEB\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f. \u9023\u643a\u7814\u4fee\u306b\u6765\u3066\u307f\u307e\u305b\u3093\u304b\uff1f\uff5e\u5316\u5b66\u7642\u6cd5\u306eknow-how \u3059\u3079\u3066\u304a\u4f1d\u3048\u3057\u307e\u3059\uff5e<br>\u4ee4\u548c5 \u5e74\u5ea6\u770c\u592e\u5730\u533a\u85ac\u85ac\u9023\u643a\u7814\u4fee\u4f1a, 2023.10\uff08WEB\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f. \u30da\u30b0\u30d5\u30a3\u30eb\u30b0\u30e9\u30b9\u30c1\u30e0\u306e\u6295\u4e0e\u30bf\u30a4\u30df\u30f3\u30b0\u306b\u3064\u3044\u3066<br>\u5730\u57df\u304c\u3093\u8a3a\u7642\u9023\u643a\u62e0\u70b9\u75c5\u9662\u85ac\u5264\u5e2b\u5408\u540c\u30bb\u30df\u30ca\u30fc, 2023.11\uff08WEB\uff09<\/li>\n\n\n\n<li>\u7cf8\u8cc0\u667a\u5b50. \u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u306e\u904b\u7528\u3068\u4e73\u304c\u3093\u6cbb\u7642\u306b\u304a\u3051\u308b\u6297\u304c\u3093\u5264\u526f\u4f5c\u7528\u30de\u30cd\u30b8\u30e1\u30f3\u30c8<br>\u7b2c15\u56de\u9e7f\u884c\u5730\u533a\u304c\u3093\u770b\u8b77\u52c9\u5f37\u4f1a, 2023.12(WEB\uff09<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2022\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u83c5\u8c37\u660e\u5fb3. \u9069\u5207\u306a\u4e8c\u6b21\u6cbb\u7642\u9078\u629e\u3068\u7d99\u7d9a\u306e\u30dd\u30a4\u30f3\u30c8. <br>Pancreatic cancer Web Seminar in Ibaraki 2022&nbsp; \u30d1\u30cd\u30ea\u30b9\u30c8\u30002022.1\uff08Web\u958b\u50ac\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3. \u5f53\u9662\u3067\u306e\u553e\u6db2\u817a\u764c\u75c7\u4f8b\u306b\u304a\u3051\u308b\u30e9\u30ed\u30c8\u30ec\u30af\u30c1\u30cb\u30d6\u306e\u4f7f\u7528\u7d4c\u9a13. <br>\u30f4\u30a1\u30a4\u30c8\u30e9\u30c3\u30af\u30d3\u00ae WEB\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\u30002022.3\uff08Web\u958b\u50ac\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3. \u304c\u3093\u30b2\u30ce\u30e0\u533b\u7642\u9023\u643a\u75c5\u9662\u3067\u306e\u53d6\u308a\u7d44\u307f NTRK\u878d\u5408\u907a\u4f1d\u5b50\u691c\u51fa\u3068\u30f4\u30a1\u30a4\u30c8\u30e9\u30c3\u30af\u30d3\u00ae\u6295\u4e0e\u7d4c\u9a13\u306e\u5171\u6709. <br>\u6176\u5fdc\u5927\u5b66\u304c\u3093\u30b2\u30ce\u30e0\u533b\u7642\u9023\u643a\u75c5\u9662\u8b1b\u6f14\u4f1a, 2022.4\uff08Web\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3. \u5f53\u9662\u306b\u304a\u3051\u308b\u80c3\u764c\u5f8c\u65b9\u6cbb\u7642\u3067\u306e\u30ed\u30f3\u30b5\u30fc\u30d5\u306e\u4f7f\u7528\u306e\u5b9f\u969b.<br> GI Cancer Chemotherapy Meeting 2022 in Mito, 2022.6\uff08Web\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3. \u304c\u3093\u30b2\u30ce\u30e0\u533b\u7642\u9023\u643a\u75c5\u9662\u3067\u306e\u53d6\u308a\u7d44\u307f\u3000NTRK\u878d\u5408\u907a\u4f1d\u5b50\u691c\u51fa\u3068\u30f4\u30a1\u30a4\u30c8\u30e9\u30c3\u30af\u30d3\u6295\u4e0e\u7d4c\u9a13\u306e\u5171\u6709. <br>\u56fd\u7acb\u304c\u3093\u7814\u7a76\u30bb\u30f3\u30bf\u30fc\u4e2d\u592e\u75c5\u9662\u304c\u3093\u30b2\u30ce\u30e0\u533b\u7642\u9023\u643a\u75c5\u9662\u8b1b\u6f14\u4f1a, 2022.7<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3. How I treat NTRK gene fusion-positive cancers.<br> \u30f4\u30a1\u30a4\u30c8\u30e9\u30c3\u30af\u30d3\u767a\u58f21\u5468\u5e74Web\u8b1b\u6f14\u4f1a, 2022.8\uff08Web\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3. \u30a8\u30f3\u30cf\u30fc\u30c4\u3092\u81e8\u5e8a\u3067\u3069\u3046\u6d3b\u304b\u3059\u304b\u3000<br>\uff0d\u5f8c\u65b9\u30e9\u30a4\u30f3\u306b\u3064\u306a\u3050\u6cbb\u7642\u3092\u8003\u3048\u308b\uff0d Gastric Cancer Web Seminar in Ibaraki, 2022.9\uff08Web\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3. \u5f53\u9662\u306b\u304a\u3051\u308b\u30e9\u30ed\u30c8\u30ec\u30af\u30c1\u30cb\u30d6\u4f7f\u7528\u7d4c\u9a13\uff5e\u51fa\u3057\u3066\u3088\u304b\u3063\u305fCGP\uff5e <br>\u5927\u962a\u5927\u5b66\u533b\u5b66\u90e8\u9644\u5c5e\u75c5\u9662\u30b2\u30ce\u30e0\u95a2\u9023\u8b1b\u6f14\u4f1a, 2022.9\uff08Web\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3. \u907a\u4f1d\u5b50\u30d1\u30cd\u30eb\u691c\u67fb\u306e\u6e2c\u5b9a\u610f\u7fa9\u306b\u3064\u3044\u3066. <br>\u8328\u57ce\u770c\u770c\u592e\u770c\u5317\u304c\u3093\u907a\u4f1d\u5b50\u30d1\u30cd\u30ebweb\u30bb\u30df\u30ca\u30fc, 2022.12<\/li>\n\n\n\n<li>\u67f4\u3053\u306e\u307f. \u30c8\u30ec\u30fc\u30b7\u30f3\u30b0\u30ec\u30dd\u30fc\u30c8\u304c\u7e4b\u3050\u60a3\u8005QOL\u6539\u5584\u3078\u306e\u9053. <br>\u770c\u592e\u5730\u533a\u85ac\u85ac\u9023\u643a\u7814\u4fee\u4f1a, 2022.10\uff08WEB\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f. \u5f53\u9662\u306b\u304a\u3051\u308bPBPM\u306e\u53d6\u308a\u7d44\u307f <br>\u9662\u5916\u51e6\u65b9\u305b\u3093\u306b\u4fc2\u308b\u7591\u7fa9\u7167\u4f1a\u7c21\u7d20\u5316\u3068\u5916\u6765\u5316\u5b66\u7642\u6cd5\u51e6\u65b9\u5165\u529b\u652f\u63f4.IBARAKI CINV web lecture, 2022.10\uff08WEB\uff09<\/li>\n\n\n\n<li>\u7cf8\u8cc0\u667a\u5b50.\u3000irAE\u5f53\u9662\u306e\u73fe\u72b6\u3068\u5916\u6765\u6cbb\u7642\u3067\u6c17\u3092\u4ed8\u3051\u3066\u3044\u308b\u3053\u3068.<br>\u304c\u3093\u5316\u5b66\u7642\u6cd5\u770b\u8b77\u5e2b\u306e\u96c6\u3044,\u30002022.9\uff08WEB\uff09<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2021\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u83c5\u8c37\u660e\u5fb3. \u7c73\u56fd\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\uff08ASCO\uff092021\u901f\u5831\u30ec\u30dd\u30fc\u30c8. poster abstract #4027\u3000\u5207\u9664\u53ef\u80fd\u98df\u9053\u764c\u306b\u5bfe\u3059\u308b\u98df\u9053\u6a5f\u80fd\u6e29\u5b58\u3092\u76ee\u7684\u3068\u3057\u305f\u5c0e\u5165DCF\u7642\u6cd5\u306b\u3088\u308bchemoselection\u306e\u7b2cII\u76f8\u8a66\u9a13\uff08CROC\u8a66\u9a13\uff09. \u6d88\u5316\u5668\u764c\u306e\u5e83\u5834\uff08GI cancer-net) https:\/\/report.gi-cancer.net\/beirinsyo2021\/index.html<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f. \u304c\u3093\u907a\u4f1d\u5b50\u30d1\u30cd\u30eb\u691c\u67fb\u306b\u304a\u3051\u308b\u591a\u8077\u7a2e\u30b5\u30dd\u30fc\u30c8\u4f53\u5236\u306e\u69cb\u7bc9. <br>\u591a\u5730\u70b9\u30e1\u30c7\u30a3\u30ab\u30eb\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9 2021.9\uff08WEB\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f. \u5916\u6765\u306b\u304a\u3051\u308b\u85ac\u85ac\u9023\u643a. \uff5e\u9023\u643a\u5145\u5b9f\u52a0\u7b97\uff5e <br>\u7b20\u9593\u5730\u533a\u85ac\u85ac\u9023\u643a\u7814\u4fee\u4f1a 2021.9\uff08WEB\uff09<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2020\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u5927\u795e\u6b63\u5b8f\uff0e\u4f75\u5b58\u75be\u60a3\u306e\u3042\u308b\u304c\u3093\u60a3\u8005\u306b\u304a\u3051\u308b\u85ac\u7269\u76f8\u4e92\u4f5c\u7528\uff5e\u6d88\u5316\u6027\u6f70\u760d\uff5e\uff0e\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u3000Essential Seminar X-Program 2020\uff0c2020\uff0e3\uff08Web\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3. \u5f53\u9662\u306b\u304a\u3051\u308b\u80c3\u304c\u3093\u306b\u5bfe\u3059\u308b\u5f8c\u65b9\u30e9\u30a4\u30f3\u6cbb\u7642. GI Cancer Chemotherapy Meeting 2020 in Mito, 2020.12 (Web\u958b\u50ac)<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3. \u5f53\u9662\u306b\u304a\u3051\u308bnivolumab\u3067\u306e\u80c3\u764c\u6cbb\u7642\uff5e\u8179\u6c34\u3001\u8179\u819c\u64ad\u7a2e\u75c7\u4f8b\u3092\u4e2d\u5fc3\u306b\uff5e\uff0e\u8328\u57ce\u770c\u592e\u770c\u5317\u4e0a\u90e8\u6d88\u5316\u7ba1Web\u30bb\u30df\u30ca\u30fc\uff0c2020.12\uff08Web\u958b\u50ac\uff09<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2019\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u9234\u6728\u9ebb\u7d17\u5b50\uff0e\u9662\u5916\u51e6\u65b9\u305b\u3093\u306b\u4fc2\u308b\u4e8b\u524d\u540c\u610f\u30d7\u30ed\u30c8\u30b3\u30eb\u306b\u3064\u3044\u3066\uff0e\u7b20\u9593\u5730\u533a\u7de9\u548c\u533b\u7642\u85ac\u5b66\u7814\u4fee\u4f1a\u30012019.1\uff08\u7b20\u9593\uff09<\/li>\n\n\n\n<li>\u7acb\u539f\u8302\u6a39\uff0e\u30aa\u30d4\u30aa\u30a4\u30c9\u3092\u9069\u6b63\u306b\u4f7f\u7528\u3057\u3066\u3044\u304f\u305f\u3081\u306b\uff5e\u4e8b\u4f8b\u691c\u8a0e\u3092\u901a\u3057\u3066\u5b66\u3076\uff5e\uff0e\u770c\u592e\u5730\u533a\u7de9\u548c\u30b1\u30a2\u30cd\u30c3\u30c8\u30ef\u30fc\u30af\u7814\u4fee\u4f1a\u30012019.3\uff08\u7b20\u9593\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0ePrecision dosing\u3092\u76ee\u6307\u3057\u305fTKI\u3068\u6297\u4f53\u533b\u85ac\u54c1\u306eTDM\uff5e\u30e9\u30d1\u30c1\u30cb\u30d6\u3001\u30a8\u30eb\u30ed\u30c1\u30cb\u30d6\u306eTDM\uff0e\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a2019\u30012019.3(\u672d\u5e4c)<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0e\u5206\u5b50\u6a19\u7684\u6297\u304c\u3093\u85ac\u3068\u80c3\u9178\u5206\u6ccc\u6291\u5236\u85ac\u3068\u306e\u85ac\u7269\u76f8\u4e92\u4f5c\u7528.\u3000\u6708\u520a\u85ac\u4e8b61\uff084\uff09\uff0c607-611\uff0c2019<\/li>\n\n\n\n<li>\u5c0f\u5cf6\u53cb\u6075\uff0e\u30da\u30b0\u30d5\u30a3\u30eb\u30b0\u30e9\u30b9\u30c1\u30e0\u306e\u6295\u4e0e\u30bf\u30a4\u30df\u30f3\u30b0\u304c\u767a\u71b1\u6027\u597d\u4e2d\u7403\u6e1b\u5c11\u75c7\u306e\u767a\u75c7\u7387\u306b\u4e0e\u3048\u308b\u5f71\u97ff\uff0e\u5730\u57df\u304c\u3093\u8a3a\u7642\u9023\u643a\u62e0\u70b9\u75c5\u9662\u85ac\u5264\u5e2b\u5408\u540c\u30bb\u30df\u30ca\u30fc\uff0c2019\uff0e8\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n<li>\u5cf6\u7530\u6d69\u548c\uff0e\u514d\u75ab\u6291\u5236\u30fb\u5316\u5b66\u7642\u6cd5\u60a3\u8005\u306b\u304a\u3051\u308bB\u578b\u809d\u708e\u30a6\u30a4\u30eb\u30b9\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u5b9f\u65bd\u72b6\u6cc1\u8abf\u67fb\uff0e\u5730\u57df\u304c\u3093\u8a3a\u7642\u9023\u643a\u62e0\u70b9\u75c5\u9662\u85ac\u5264\u5e2b\u5408\u540c\u30bb\u30df\u30ca\u30fc\uff0c2019\uff0e8\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0e\u5f53\u9662\u306b\u304a\u3051\u308birAE\u767a\u73fe\u72b6\u6cc1\u3068\u305d\u306e\u5bfe\u7b56\uff0e\u4e73\u304c\u3093\u6700\u65b0\u60c5\u5831\u30a2\u30fc\u30d9\u30f3\u30c82019\uff0c2019\uff0e11\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0e\u304c\u3093\u6027\u75bc\u75db\u306e\u85ac\u7269\u6cbb\u7642\u306b\u3064\u3044\u3066\uff0ePharmacist Director Seminar2019\uff0c2019\uff0e12\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0e\u7d4c\u53e3\u5206\u5b50\u6a19\u7684\u6297\u304c\u3093\u85ac\u306eTDM\uff0e\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u85ac\u5b66\u4f1a \u5b9f\u52d9\u30b9\u30ad\u30eb\u30a2\u30c3\u30d7\u30bb\u30df\u30ca\u30fc2019\uff0c2019\uff0e12\uff08\u6771\u4eac\uff09<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2018\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u5927\u795e\u6b63\u5b8f. \u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u306b\u304a\u3051\u308b\u30ab\u30eb\u30dc\u30d7\u30e9\u30c1\u30f3\u30ec\u30b8\u30e1\u30f3\u5236\u5410\u7642\u6cd5\u306e\u73fe\u72b6\u30fb\u8ab2\u984c\u3068\u4eca\u5f8c\u306e\u5c55\u958b. \u770c\u592eCINV\u30bb\u30df\u30ca\u30fc, 2018.<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0e\u5206\u5b50\u6a19\u7684\u6297\u304c\u3093\u5264\u306eTDM\u8a3a\u7642\u5831\u916c\u62e1\u5927\u3092\u76ee\u6307\u3057\u3066\uff5e\u80ba\u764c\u9818\u57df\u306b\u304a\u3051\u308b\u304c\u3093\u30c1\u30ed\u30b7\u30f3\u30ad\u30ca\u30fc\u30bc\u963b\u5bb3\u85ac\u306eTDM. \u7b2c35\u56de\u65e5\u672cTDM\u5b66\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\u30012018.5\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0e\u5916\u6765\u5316\u5b66\u7642\u6cd5\u306b\u304a\u3051\u308b\u526f\u4f5c\u7528\u5bfe\u7b56\uff0e\u7b2c3\u56de\u9e7f\u5cf6\u5730\u533a\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u8b1b\u6f14\u4f1a\u30012018.6\uff08\u9e7f\u5d8b\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u85ac\u306e\u526f\u4f5c\u7528\u5bfe\u7b56\uff0e\u7b20\u9593\u5730\u533a\u85ac\u85ac\u9023\u643a\u7814\u4fee\u4f1a\u30012018.6\uff08\u7b20\u9593\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0e\u8328\u57ce\u770c\u304c\u3093\u8a3a\u7642\u9023\u643a\u5354\u8b70\u4f1a\u7814\u4fee\u90e8\u4f1a\u85ac\u5264\u5e2b\u5206\u79d1\u4f1a\u306e\u6d3b\u52d5\u7d39\u4ecb\uff5e\u591a\u65bd\u8a2d\u5171\u540c\u81e8\u5e8a\u7814\u7a76\u30b0\u30eb\u30fc\u30d7\u306e\u69cb\u7bc9\uff5e\uff0e\u5730\u57df\u304c\u3093\u8a3a\u7642\u9023\u643a\u62e0\u70b9\u75c5\u9662\u85ac\u5264\u5e2b\u30bb\u30df\u30ca\u30fc\u30012018.8\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0e\u5206\u5b50\u6a19\u7684\u6cbb\u7642\u85ac\u306b\u304a\u3051\u308b\u526f\u4f5c\u7528\u5bfe\u7b56\uff0e\u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u95a2\u6771\u30d6\u30ed\u30c3\u30af\u7b2c48\u56de\u5b66\u8853\u5927\u4f1a\u30012018.8(\u5b87\u90fd\u5bae)<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0e\u30c1\u30ed\u30b7\u30f3\u30ad\u30ca\uff0d\u30bc\u963b\u5bb3\u85ac\u306e\u85ac\u7269\u76f8\u4e92\u4f5c\u7528\uff0e\u7b2c\uff12\uff18\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a\u30012018.11\uff08\u795e\u6238\uff09<\/li>\n\n\n\n<li>\u5927\u795e\u6b63\u5b8f\uff0e\u5f53\u9662\u306b\u304a\u3051\u308birAE\u767a\u73fe\u72b6\u6cc1\uff0e\u5e73\u621030\u5e74\u5ea6\u304c\u3093\u533b\u7642\u30bb\u30df\u30ca\u30fc\u30012018.11\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n<li>\u9ad8\u7530\u6e05\u5b50. \u96fb\u8a71\u76f8\u8ac7\u306b\u3088\u308b\u652f\u63f4.\u304c\u3093\u652f\u6301\u7642\u6cd5\u8b1b\u6f14\u4f1a, 2018.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2017\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u5927\u795e\u6b63\u5b8f. \u304c\u3093\u85ac\u7269\u7642\u6cd5\u3078\u306e\u85ac\u5264\u5e2b\u306e\u95a2\u308f\u308a. <br>Advanced Communication to Improve Oncology Network, 2017.<\/li>\n\n\n\n<li>\u9ad8\u7530\u6e05\u5b50. \u60a3\u8005\u5b85\u8a2a\u554f\u3092\u901a\u3057\u3066\u5730\u57df\u30b5\u30fc\u30d3\u30b9\u306b\u3064\u306a\u3052\u305f\u304c\u3093\u5316\u5b66\u7642\u6cd5\u770b\u8b77\u8a8d\u5b9a\u770b\u8b77\u5e2b\u306e\u52d5\u304d.<br>\u6708\u520a\u30ca\u30fc\u30b9\u30de\u30cd\u30fc\u30b8\u30e3\u30fc 2017; pp71-75.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">2010\u5e74<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u83ca\u5730\u5343\u6625, \u5927\u795e\u6b63\u5b8f, \u4e09\u6a4b\u5f70\u4e00, \u77f3\u9ed2\u613c\u543e, \u6d5c\u672c\u5eb7\u592b, \u5c0f\u5cf6\u5bdb. <br>\u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u306e\u30c7\u30b6\u30a4\u30f3\u3068\u30de\u30cd\u30fc\u30b8\u30e1\u30f3\u30c8. \u591a\u5730\u70b9\u5408\u540c\u30e1\u30c7\u30a3\u30ab\u30eb\u30fb\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9. 2010\u5e744\u6708.<\/li>\n<\/ol>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-vk-blocks-border-box vk_borderBox vk_borderBox-background-transparent is-style-vk_borderBox-style-solid-kado-tit-onborder vk_block-margin-lg--margin-top\"><div class=\"vk_borderBox_title_container\"><i class=\"\"><\/i><h4 class=\"vk_borderBox_title\">\u5f53\u30bb\u30f3\u30bf\u30fc\u306e\u53d6\u7d44\u307f<\/h4><\/div><div class=\"vk_borderBox_body\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:20%\"><div class=\"wp-block-image vk_block-margin-md--margin-top\">\n<figure class=\"aligncenter size-full\"><a href=\"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-content\/uploads\/2022\/12\/sonotanokatsudo.jpg\"><img loading=\"lazy\" decoding=\"async\" width=\"228\" height=\"132\" src=\"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-content\/uploads\/2022\/12\/sonotanokatsudo.jpg\" alt=\"\u305d\u306e\u4ed6\u306e\u6d3b\u52d5\" class=\"wp-image-3719\"\/><\/a><\/figure>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:80%\">\n<p>\u3000\u5f53\u9662\u306b\u306f\u3001\u304c\u3093\u5316\u5b66\u7642\u6cd5\u770b\u8b77\u8a8d\u5b9a\u770b\u8b77\u5e2b3\u540d\u3001\u304c\u3093\u85ac\u7269\u7642\u6cd5\u8a8d\u5b9a\u85ac\u5264\u5e2b2\u540d\u304c\u5728\u7c4d\u3057\u3001\u3046\u3061\u770b\u8b77\u5e2b1\u540d\u3001\u85ac\u5264\u5e2b1\u540d\u304c\u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u306b\u52e4\u52d9\u3057\u3066\u3044\u307e\u3059\u3002\u304c\u3093\u85ac\u7269\u7642\u6cd5\u8a8d\u5b9a\u85ac\u5264\u5e2b\u306e\u3046\u30611\u540d\u306f\u3001\u5e73\u621028\u5e74\u5ea6\u3001\u304c\u3093\u5c02\u9580\u85ac\u5264\u5e2b\u306e\u8cc7\u683c\u3092\u53d6\u5f97\u3057\u307e\u3057\u305f\u3002<br>\u3000\u304c\u3093\u60a3\u8005\u306e\u5897\u52a0\u3001\u6297\u304c\u3093\u5264\u306e\u9032\u6b69\u3001\u5206\u5b50\u6a19\u7684\u85ac\u306e\u51fa\u73fe\u306b\u3088\u308a\u4eca\u5f8c\u3082\u5316\u5b66\u7642\u6cd5\u30bb\u30f3\u30bf\u30fc\u306b\u304a\u3051\u308b\u75c7\u4f8b\u6570\u304c\u5897\u52a0\u3057\u3066\u3044\u304f\u3053\u3068\u304c\u4e88\u60f3\u3055\u308c\u3001\u3055\u3089\u306a\u308b\u5b89\u5168\u6027\u306e\u78ba\u4fdd\u306b\u5fc3\u304c\u3051\u3066\u3044\u304f\u6240\u5b58\u3067\u3059\u3002\u8328\u57ce\u770c\u306e\u304c\u3093\u8a3a\u7642\u62e0\u70b9\u75c5\u9662\u3068\u3057\u3066\u5b89\u5168\u304b\u3064\u78ba\u5b9f\u306a\u5316\u5b66\u7642\u6cd5\u3092\u63d0\u4f9b\u3059\u308b\u305f\u3081\u306b\u3001\u4eca\u5f8c\u3068\u3082\u5c02\u5c5e\u306e\u533b\u5e2b\u3001\u770b\u8b77\u5e2b\u3001\u85ac\u5264\u5e2b\u3092\u4e2d\u5fc3\u3068\u3057\u305f\u30c1\u30fc\u30e0\u533b\u7642\u306b\u3088\u308a\u3001\u8cea\u306e\u9ad8\u3044\u5316\u5b66\u7642\u6cd5\u306e\u63d0\u4f9b\u3092\u7d99\u7d9a\u3057\u3066\u884c\u304f\u6240\u5b58\u3067\u3042\u308a\u3001\u307e\u305f\u5c02\u9580\u7684\u77e5\u8b58\u3001\u6280\u80fd\u3001\u7d4c\u9a13\u3092\u6709\u3059\u308b\u533b\u5e2b\u3001\u770b\u8b77\u5e2b\u3001\u85ac\u5264\u5e2b\u7b49\u30b9\u30bf\u30c3\u30d5\u306e\u990a\u6210\u304c\u5fc5\u8981\u3067\u3042\u308b\u3068\u8003\u3048\u3066\u3044\u307e\u3059\u3002<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":141,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","vk-ltc-link":"","vk-ltc-target":"0"},"class_list":["post-161","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/comments?post=161"}],"version-history":[{"count":22,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/161\/revisions"}],"predecessor-version":[{"id":25296,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/161\/revisions\/25296"}],"up":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/141"}],"wp:attachment":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/media?parent=161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}